[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2342
1. Kager L, Cheok M, Yang W, Zaza G, Cheng Q, Panetta JC, Pui CH, Downing JR, Relling MV, Evans WE: Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest; 2005 Jan;115(1):110-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics.
  • The ability of leukemia cells to accumulate methotrexate polyglutamate (MTXPG) is an important determinant of the antileukemic effects of methotrexate (MTX).
  • We measured in vivo MTXPG accumulation in leukemia cells from 101 children with acute lymphoblastic leukemia (ALL) and established that B-lineage ALL with either TEL-AML1 or E2A-PBX1 gene fusion, or T-lineage ALL, accumulates significantly lower MTXPG compared with B-lineage ALL without these genetic abnormalities or compared with hyperdiploid (fewer than 50 chromosomes) ALL.
  • To elucidate mechanisms underlying these differences in MTXPG accumulation, we used oligonucleotide microarrays to analyze expression of 32 folate pathway genes in diagnostic leukemia cells from 197 children.
  • These findings reveal distinct mechanisms of subtype-specific differences in MTXPG accumulation and point to new strategies to overcome these potential causes of treatment failure in childhood ALL.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827850849 for PMID:15630450 [PharmGKB] .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 Sep 1;104(5):1435-41 [15142881.001]
  • [Cites] Mol Cell Biochem. 1981 Aug 11;38 Spec No(Pt 1):19-48 [7027025.001]
  • [Cites] N Engl J Med. 1983 Nov 3;309(18):1094-104 [6353235.001]
  • [Cites] J Biol Chem. 1985 Aug 15;260(17):9720-6 [2410416.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Aug;82(15):4881-5 [3860829.001]
  • [Cites] J Clin Invest. 1985 Oct;76(4):1323-9 [2414316.001]
  • [Cites] Blood. 1990 Jul 1;76(1):117-22 [2364165.001]
  • [Cites] J Clin Oncol. 1990 Aug;8(8):1380-8 [2380759.001]
  • [Cites] Math Biosci. 1990 Apr;99(1):105-18 [2134510.001]
  • [Cites] Blood. 1992 Sep 1;80(5):1158-62 [1381235.001]
  • [Cites] Blood. 1992 Sep 1;80(5):1316-23 [1381244.001]
  • [Cites] Blood. 1994 Jul 15;84(2):564-9 [7517720.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1667-72 [8040679.001]
  • [Cites] J Clin Invest. 1994 Nov;94(5):1996-2001 [7525652.001]
  • [Cites] J Clin Invest. 1996 Jan 1;97(1):73-80 [8550853.001]
  • [Cites] N Engl J Med. 1996 Oct 3;335(14):1041-8 [8793930.001]
  • [Cites] Blood. 1997 Feb 1;89(3):1013-8 [9028333.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2193-9 [9187120.001]
  • [Cites] Mol Pharmacol. 1997 Jul;52(1):155-63 [9224825.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7225-32 [11585759.001]
  • [Cites] Ugeskr Laeger. 2008 Jan 28;170(5):328-30 [18252159.001]
  • [Cites] Biochim Biophys Acta. 2002 Jun 21;1602(2):131-50 [12020800.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3144-50 [12036927.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1240-7 [12149204.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):5035-40 [12208758.001]
  • [Cites] Br J Haematol. 2003 Feb;120(3):484-7 [12580965.001]
  • [Cites] J Biol Chem. 2003 Feb 28;278(9):6680-6 [12486126.001]
  • [Cites] Biochem Pharmacol. 2003 Mar 1;65(5):765-71 [12628490.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5538-43 [14500392.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] JAMA. 2003 Oct 15;290(15):2001-7 [14559953.001]
  • [Cites] Semin Oncol. 1999 Apr;26(2 Suppl 6):11-23 [10598550.001]
  • [Cites] Pharmacol Ther. 2000 Mar;85(3):207-15 [10739875.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • [Cites] J Biol Chem. 2000 Nov 10;275(45):35646-55 [10978335.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2166-75 [11187907.001]
  • [Cites] Leukemia. 2001 Jul;15(7):1081-8 [11455977.001]
  • [Cites] Blood. 1998 Feb 1;91(3):735-46 [9446631.001]
  • [Cites] Clin Cancer Res. 1998 Sep;4(9):2169-77 [9748136.001]
  • [Cites] Int J Cancer. 1998 Oct 5;78(2):176-81 [9754649.001]
  • [Cites] Nat Genet. 1999 Jan;21(1 Suppl):20-4 [9915496.001]
  • [Cites] Leuk Lymphoma. 1998 Nov;31(5-6):507-19 [9922041.001]
  • [Cites] Blood. 1999 Mar 1;93(5):1643-50 [10029593.001]
  • [Cites] Blood. 1999 Mar 1;93(5):1677-83 [10029597.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2532-5 [10363967.001]
  • [Cites] Methods Mol Biol. 2002;184:143-68 [11889711.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7431-57 [14576850.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5171-7 [14613996.001]
  • [Cites] Biochem Pharmacol. 2004 Apr 15;67(8):1541-8 [15041471.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Pharmacogenetics. 2004 Aug;14(8):557-67 [15284538.001]
  • (PMID = 15630450.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA71907-07; United States / NCI NIH HHS / CA / R37 CA36401; United States / NCI NIH HHS / CA / P01 CA071907; United States / NIGMS NIH HHS / GM / U01 GM061393; United States / NCI NIH HHS / CA / R01 CA078224; United States / NCI NIH HHS / CA / R37 CA036401; United States / NCI NIH HHS / CA / CA21765; United States / NIGMS NIH HHS / GM / U01 GM61393; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / R01 CA051001; United States / NCI NIH HHS / CA / R01 CA78224; United States / NCI NIH HHS / CA / R01 CA51001
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 25513-46-6 / Polyglutamic Acid; 82334-40-5 / methotrexate polyglutamate; 9007-49-2 / DNA; 935E97BOY8 / Folic Acid; EC 2.1.1.45 / Thymidylate Synthase; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC539195
  •  go-up   go-down


2. Kim M, Yim SH, Cho NS, Kang SH, Ko DH, Oh B, Kim TY, Min HJ, She CJ, Kang HJ, Shin HY, Ahn HS, Yoon SS, Kim BK, Shin HR, Han KS, Cho HI, Lee DS: Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study. Cancer Genet Cytogenet; 2009 Nov;195(1):59-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study.
  • The biological behavior of childhood B-lineage acute lymphoblastic leukemia (B-ALL) is different from that of adults.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p15 / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Gene Deletion. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics


3. Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ, Camitta BM, Gaynon PS, Carroll WL: Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. J Clin Oncol; 2008 Aug 20;26(24):3971-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected].
  • PURPOSE: Treatment of childhood relapsed acute lymphoblastic leukemia (ALL) remains a significant challenge.
  • Five of seven patients with T-cell ALL (T-ALL) failed to achieve CR2.
  • CONCLUSION: The AALL01P2 regimen is a tolerable and active reinduction platform, suitable for testing in combination with novel agents in B-precursor ALL.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Sep 1;96(5):1709-15 [10961868.001]
  • [Cites] Med Pediatr Oncol. 2000 May;34(5):313-8 [10797352.001]
  • [Cites] Lancet. 2001 Oct 13;358(9289):1239-41 [11675066.001]
  • [Cites] Br J Haematol. 2002 Sep;118(3):741-7 [12181040.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1668-72 [12200679.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1566-72 [12886244.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):396-405 [14616997.001]
  • [Cites] Leukemia. 2004 Mar;18(3):499-504 [14981525.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Cancer. 1980 Jun 15;45(12):3090-4 [6930318.001]
  • [Cites] J Clin Oncol. 1985 Jul;3(7):998-1004 [3860629.001]
  • [Cites] Blood. 1988 Oct;72(4):1286-92 [3167209.001]
  • [Cites] Blood. 1991 Sep 1;78(5):1166-72 [1878583.001]
  • [Cites] Blood. 1993 Feb 1;81(3):602-9 [8427957.001]
  • [Cites] Med Pediatr Oncol. 1993;21(7):470-6 [8341213.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):34-8 [7743235.001]
  • [Cites] Med Pediatr Oncol. 1995 Nov;25(5):372-8 [7674994.001]
  • [Cites] Blood. 1996 Aug 1;88(3):831-7 [8704238.001]
  • [Cites] Med Pediatr Oncol. 1996 Dec;27(6):505-14 [8888809.001]
  • [Cites] Br J Haematol. 1997 Dec;99(3):671-7 [9401083.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4072-9 [9834212.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):368-76 [15599932.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):67-75 [15982346.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7942-50 [16258094.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3150-6 [16717292.001]
  • [Cites] Blood. 2006 Jul 15;108(2):711-7 [16822902.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5750-62 [17179109.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5477-85 [18388178.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3756-62 [18669463.001]
  • [Cites] Pediatr Blood Cancer. 2004 Oct;43(5):571-9 [15382275.001]
  • [Cites] Haematologica. 2000 Nov;85(11 Suppl):47-53 [11268324.001]
  • [Cites] Br J Haematol. 2000 Mar;108(3):531-43 [10759711.001]
  • [ErratumIn] J Clin Oncol. 2008 Oct 1;26(28): 4697.
  • (PMID = 18711187.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21CA110344; United States / NCI NIH HHS / CA / U10 CA98543
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ZRP63D75JW / Idarubicin
  • [Other-IDs] NLM/ PMC2654313
  •  go-up   go-down


Advertisement
4. Oeffinger KC: Are survivors of acute lymphoblastic leukemia (ALL) at increased risk of cardiovascular disease? Pediatr Blood Cancer; 2008 Feb;50(2 Suppl):462-7; discussion 468
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are survivors of acute lymphoblastic leukemia (ALL) at increased risk of cardiovascular disease?
  • Through a variety of different mechanisms, it appears that survivors of childhood acute lymphoblastic leukemia have an increased prevalence of several cardiovascular risk factors and thus are at increased risk for developing cardiovascular disease.
  • The aim of this paper is to describe the current understanding of particular risk factors, including obesity, physical inactivity, dyslipidemia, insulin resistance, and metabolic syndrome, that may contribute to cardiovascular disease in survivors of childhood ALL.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18064658.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA100474-04; United States / NCI NIH HHS / CA / R01 CA100474; United States / NCI NIH HHS / CA / R01 CA100474-04; United States / NCI NIH HHS / CA / R01-CA-100474
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


5. Kerst G, Kreyenberg H, Roth C, Well C, Dietz K, Coustan-Smith E, Campana D, Koscielniak E, Niemeyer C, Schlegel PG, Müller I, Niethammer D, Bader P: Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol; 2005 Mar;128(6):774-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR.
  • Minimal (i.e. submicroscopic) residual disease (MRD) predicts outcome in childhood acute lymphoblastic leukaemia (ALL).
  • [MeSH-major] Biomarkers, Tumor / analysis. Flow Cytometry / methods. Polymerase Chain Reaction / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755280.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


6. Zhang LP, Cheng YF, Liu GL, Lu AD, Liu YR, Wang H: [The clinical significance of detecting minimal residual disease in acute childhood B-cell lymphoblastic leukemia with flow cytometry]. Zhonghua Er Ke Za Zhi; 2005 Jul;43(7):481-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical significance of detecting minimal residual disease in acute childhood B-cell lymphoblastic leukemia with flow cytometry].
  • OBJECTIVE: Flow cytometry may be used to detect minimal residual disease (MRD) in acute lymphoblastic leukemia because leukemic cells often display aberrant phenotypes when compared to normal cells.
  • The investigators also aimed to study the value of the detection of MRD by flow cytometry in childhood B-ALL without effective antibody combinations.
  • METHODS: Thirty-six cases of childhood B-ALL with effective antibody combinations were performed MRD analysis after induction therapy.
  • (1) Forty-two cases of childhood B-ALL were screened for antibody combinations of interest and were identified in 86% (36/42) of the cases.
  • CONCLUSION:. (1) Flow cytometry is a sensitive and specific method for detecting MRD of childhood ALL, and could predict the coming relapse. (2) Patients with MRD levels > 10(-3) had poor prognosis. (3) The levels of MRD at month 9 and 12 had prognostic value. (4) The value of antibody combinations consisting of CD(45)/CD(19)/CD(10)/CD(34) and CD(45)/CD(19)/CD(20)/CD(22) should be further investigated in patients without effective antibody combinations.
  • [MeSH-major] B-Lymphocyte Subsets / immunology. Flow Cytometry. Immunophenotyping. Neoplasm, Residual / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis


7. John E, Laskow TC, Buchser WJ, Pitt BR, Basse PH, Butterfield LH, Kalinski P, Lotze MT: Zinc in innate and adaptive tumor immunity. J Transl Med; 2010 Nov 18;8:118
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is an essential trace element, critical for cell growth, development and differentiation, DNA synthesis, RNA transcription, cell division, and cell activation.
  • Zinc deficiency has adverse consequences during embryogenesis and early childhood development, particularly on immune functioning.
  • Zinc depletion induces cell death via apoptosis (or necrosis if apoptotic pathways are blocked) while sufficient zinc levels allows maintenance of autophagy.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Rev Neurobiol. 1989;31:145-238 [2689380.001]
  • [Cites] Free Radic Biol Med. 1990;9(3):229-33 [2272531.001]
  • [Cites] Biochem Int. 1991 Aug;24(6):1093-101 [1781788.001]
  • [Cites] Int J Cancer. 1992 Oct 21;52(4):604-8 [1328072.001]
  • [Cites] Physiol Rev. 1993 Jan;73(1):79-118 [8419966.001]
  • [Cites] Biochem J. 1993 Dec 1;296 ( Pt 2):403-8 [8257431.001]
  • [Cites] Science. 1995 Mar 10;267(5203):1456-62 [7878464.001]
  • [Cites] J Nutr. 1995 Apr;125(4):823-9 [7722683.001]
  • [Cites] Nutrition. 1995 Jan-Feb;11(1 Suppl):93-9 [7749260.001]
  • [Cites] Kokubyo Gakkai Zasshi. 1995 Mar;62(1):78-93 [7751801.001]
  • [Cites] Ann Clin Lab Sci. 1995 Mar-Apr;25(2):134-42 [7785963.001]
  • [Cites] Neurochem Int. 1995 Jul;27(1):23-33 [7655345.001]
  • [Cites] J Immunol. 1995 Nov 1;155(9):4143-6 [7594568.001]
  • [Cites] Teratology. 1995 Sep;52(3):149-59 [8638255.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2454-8 [8637895.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 May 28;93(11):5624-8 [8643627.001]
  • [Cites] Nature. 2004 Dec 23;432(7020):1032-6 [15525940.001]
  • [Cites] Cell Calcium. 2005 Mar;37(3):225-32 [15670869.001]
  • [Cites] Cell. 2005 Jan 28;120(2):159-62 [15680321.001]
  • [Cites] Nat Rev Immunol. 2005 Apr;5(4):331-42 [15803152.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 16;335(1):162-7 [16055081.001]
  • [Cites] J Surg Oncol. 2005 Sep 1;91(3):204-8 [16118778.001]
  • [Cites] J Immunol. 2005 Oct 1;175(7):4697-705 [16177117.001]
  • [Cites] Trends Cell Biol. 1999 Dec;9(12):M49-52 [10611682.001]
  • [Cites] Am J Clin Nutr. 2000 Jan;71(1):81-7 [10617950.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • [Cites] J Nutr. 2000 May;130(5):1085-8 [10801901.001]
  • [Cites] J Nutr. 2000 May;130(5S Suppl):1399S-406S [10801951.001]
  • [Cites] J Nutr. 2000 May;130(5S Suppl):1459S-66S [10801960.001]
  • [Cites] Eur J Biochem. 2000 Jun;267(12):3469-76 [10848962.001]
  • [Cites] J Infect Dis. 2000 Sep;182 Suppl 1:S62-8 [10944485.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Sep;294(3):997-1008 [10945852.001]
  • [Cites] Annu Rev Biochem. 2000;69:217-45 [10966458.001]
  • [Cites] Cell. 2000 Sep 1;102(5):549-52 [11007473.001]
  • [Cites] J Infect Dis. 2000 Sep;182 Suppl 1:S85-92 [11041715.001]
  • [Cites] Am J Clin Nutr. 2000 Dec;72(6):1516-22 [11101480.001]
  • [Cites] Proc Nutr Soc. 2000 Nov;59(4):541-52 [11115789.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Dec 20;279(2):607-14 [11118333.001]
  • [Cites] J Biochem. 2000 Dec;128(6):933-9 [11098135.001]
  • [Cites] Immunity. 2001 Jan;14(1):93-104 [11163233.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1734-9 [11172020.001]
  • [Cites] J Am Diet Assoc. 2001 Mar;101(3):294-301 [11269606.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Apr 13;282(4):1067-73 [11352661.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22258-64 [11301334.001]
  • [Cites] J Lab Clin Med. 2001 Oct;138(4):250-6 [11574819.001]
  • [Cites] J Neurophysiol. 2001 Nov;86(5):2597-604 [11698545.001]
  • [Cites] Biometals. 2001 Sep-Dec;14(3-4):315-30 [11831462.001]
  • [Cites] J Nutr. 2002 May;132(5):974-9 [11983824.001]
  • [Cites] Am J Clin Nutr. 2002 Jun;75(6):1062-71 [12036814.001]
  • [Cites] J Biol Chem. 2002 Oct 18;277(42):39209-16 [12161443.001]
  • [Cites] Eukaryot Cell. 2002 Feb;1(1):11-21 [12455967.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Apr 4;303(2):586-93 [12659860.001]
  • [Cites] Mech Ageing Dev. 2003 Apr;124(4):459-68 [12714254.001]
  • [Cites] J Nutr. 2003 May;133(5 Suppl 1):1452S-6S [12730441.001]
  • [Cites] FEMS Microbiol Rev. 2003 Jun;27(2-3):291-311 [12829272.001]
  • [Cites] Mol Med. 2003 Mar-Apr;9(3-4):65-76 [12865942.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2003 Nov;285(5):E1095-102 [12812920.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12301-6 [14530385.001]
  • [Cites] Nat Immunol. 2003 Dec;4(12):1164-5 [14639465.001]
  • [Cites] Cell Mol Life Sci. 2004 Jan;61(1):49-68 [14704853.001]
  • [Cites] Pflugers Arch. 2004 Feb;447(5):744-51 [12748859.001]
  • [Cites] Pflugers Arch. 2004 Feb;447(5):796-800 [12748861.001]
  • [Cites] Mol Biol Cell. 2004 Mar;15(3):1101-11 [14699058.001]
  • [Cites] Cell Immunol. 1979 Sep 15;47(1):100-5 [509529.001]
  • [Cites] J Immunol. 1980 Jun;124(6):2650-5 [6966295.001]
  • [Cites] Cancer. 1981 Apr 1;47(7):1845-8 [7226079.001]
  • [Cites] Int J Biochem. 1982;14(11):983-90 [7141075.001]
  • [Cites] Cancer. 1983 Sep 1;52(5):868-72 [6871828.001]
  • [Cites] Eur J Immunol. 1984 May;14(5):454-8 [6609827.001]
  • [Cites] J Lab Clin Med. 1985 Jan;105(1):19-22 [3968462.001]
  • [Cites] J Pharmacol. 1985 Oct-Dec;16(4):344-52 [2419703.001]
  • [Cites] Cell Death Differ. 2001 Mar;8(3):265-72 [11319609.001]
  • [Cites] Neoplasma. 1986;33(1):85-90 [3960212.001]
  • [Cites] J Clin Invest. 1988 Oct;82(4):1202-10 [3262625.001]
  • [Cites] Biochem J. 2006 Feb 15;394(Pt 1):275-83 [16236025.001]
  • [Cites] Eur J Immunol. 2006 Feb;36(2):421-30 [16402406.001]
  • [Cites] Biogerontology. 2005 Dec;6(6):407-13 [16518702.001]
  • [Cites] J Trace Elem Med Biol. 2006;20(1):3-18 [16632171.001]
  • [Cites] Curr Opin Pharmacol. 2006 Jun;6(3):237-43 [16540372.001]
  • [Cites] Mol Cancer. 2006;5:17 [16700911.001]
  • [Cites] J Immunol. 2006 Jul 15;177(2):1296-305 [16818790.001]
  • [Cites] J Biol Chem. 2006 Aug 25;281(34):24085-9 [16793761.001]
  • [Cites] Nat Immunol. 2006 Sep;7(9):971-7 [16892068.001]
  • [Cites] Toxicol Lett. 2006 Oct 25;166(3):222-8 [16930873.001]
  • [Cites] Oncogene. 2006 Oct 30;25(51):6680-4 [17072321.001]
  • [Cites] Biogerontology. 2006 Oct-Dec;7(5-6):357-65 [16955215.001]
  • [Cites] J Biol Inorg Chem. 2006 Nov;11(8):1049-62 [16924557.001]
  • [Cites] Exp Gerontol. 2006 Nov;41(11):1094-107 [17030107.001]
  • [Cites] Transl Res. 2006 Dec;148(6):325-33 [17162254.001]
  • [Cites] ACS Chem Biol. 2006 Mar 17;1(2):103-11 [17163650.001]
  • [Cites] J Mol Biol. 2007 Feb 2;365(5):1417-28 [17118402.001]
  • [Cites] Acta Physiol Hung. 1989;74(2):195-9 [2603734.001]
  • [Cites] Biochem Soc Trans. 1990 Apr;18(2):299-301 [2379727.001]
  • [Cites] Mol Cancer. 2007;6:37 [17550612.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4A):1941-3 [17649800.001]
  • [Cites] J Immunol. 2007 Sep 15;179(6):4180-6 [17785857.001]
  • [Cites] J Neurosci Res. 2007 Oct;85(13):2844-55 [17628505.001]
  • [Cites] Eur J Dermatol. 2007 Nov-Dec;17(6):492-6 [17951128.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18636-41 [18003899.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):368-73 [17980503.001]
  • [Cites] Mol Immunol. 2008 Mar;45(6):1633-45 [18207244.001]
  • [Cites] J Neurosci. 2008 Mar 19;28(12):3114-22 [18354014.001]
  • [Cites] Int J Dermatol. 2008 Apr;47(4):372-3 [18377601.001]
  • [Cites] Exp Gerontol. 2008 May;43(5):488-92 [18068923.001]
  • [Cites] Exp Gerontol. 2008 May;43(5):462-71 [18215484.001]
  • [Cites] Exp Gerontol. 2008 May;43(5):452-61 [18304769.001]
  • [Cites] Am J Clin Nutr. 2008 May;87(5):1530-4 [18469280.001]
  • [Cites] Biometals. 2008 Aug;21(4):405-16 [18097638.001]
  • [Cites] Nat Immunol. 2008 Sep;9(9):1055-64 [18660811.001]
  • [Cites] Toxicol Appl Pharmacol. 2008 Sep 1;231(2):260-6 [18513776.001]
  • [Cites] Neuropharmacology. 1996 May;35(5):599-603 [8887968.001]
  • [Cites] Proc Assoc Am Physicians. 1997 Jan;109(1):68-77 [9010918.001]
  • [Cites] Brain Res. 1996 Dec 16;743(1-2):362-5 [9017270.001]
  • [Cites] J Nutr. 1997 Jul;127(7):1290-6 [9202082.001]
  • [Cites] Am J Physiol. 1997 Jun;272(6 Pt 1):E1002-7 [9227444.001]
  • [Cites] Nat Struct Biol. 1997 Aug;4(8):635-43 [9253413.001]
  • [Cites] Cornea. 1997 Sep;16(5):550-5 [9294688.001]
  • [Cites] Br Med Bull. 1997;53(3):451-65 [9374030.001]
  • [Cites] Immunol Today. 1997 Nov;18(11):519-21 [9386346.001]
  • [Cites] J Am Coll Nutr. 1998 Dec;17(6):556-63 [9853534.001]
  • [Cites] J Biol Chem. 1999 Feb 19;274(8):5053-60 [9988752.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2414-9 [10051656.001]
  • [Cites] Clin Exp Immunol. 1999 Apr;116(1):19-27 [10209500.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2838-42 [10383143.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Nov;5(11):920-31 [15520811.001]
  • [Cites] Am J Med. 1961 Oct;31:532-46 [14488490.001]
  • [Cites] Science. 2004 Nov 5;306(5698):990-5 [15528435.001]
  • [Cites] J Leukoc Biol. 2009 Aug;86(2):337-48 [19401385.001]
  • [Cites] Biogerontology. 2009 Oct;10(5):593-604 [19043799.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2009 Nov;12(6):646-52 [19710611.001]
  • [Cites] Neurotox Res. 2010 Jan;17(1):1-14 [19784710.001]
  • [Cites] Biochim Biophys Acta. 2010 Jan-Feb;1799(1-2):131-40 [20123075.001]
  • [Cites] Immunity. 2010 Feb 26;32(2):227-39 [20171125.001]
  • [Cites] Toxicol Appl Pharmacol. 2010 Mar 15;243(3):405-19 [20043934.001]
  • [Cites] Int J Epidemiol. 2010 Apr;39 Suppl 1:i63-9 [20348128.001]
  • [Cites] J Nutr. 2010 May;140(5):1049-56 [20237063.001]
  • [Cites] Int Immunol. 2010 May;22(5):375-86 [20215335.001]
  • [Cites] Eur J Immunol. 2010 May;40(5):1496-503 [20201035.001]
  • [Cites] Mol Immunol. 2010 Jun;47(10):1882-9 [20417561.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2010 Jun;298(6):L744-54 [20207754.001]
  • [Cites] Exp Biol Med (Maywood). 2010 Jun;235(6):741-50 [20511678.001]
  • [Cites] Int J Epidemiol. 2010 Jun;39(3):795-808 [20156999.001]
  • [Cites] Glia. 2010 Aug;58(10):1186-96 [20544854.001]
  • [Cites] Mol Cell Biol. 2010 Aug;30(16):3929-42 [20547752.001]
  • [Cites] J Leukoc Biol. 2010 Sep;88(3):589-96 [20551211.001]
  • [Cites] Apoptosis. 2010 Oct;15(10):1177-86 [20567904.001]
  • [Cites] Biometals. 2010 Dec;23(6):997-1013 [20524045.001]
  • [Cites] Biochim Biophys Acta. 2010 Oct-Dec;1799(10-12):717-25 [20594930.001]
  • [Cites] J Nutr Biochem. 2011 Jan;22(1):79-88 [20392624.001]
  • [Cites] Biometals. 2009 Dec;22(6):1031-40 [19609684.001]
  • [Cites] Cell Death Differ. 2005 Nov;12 Suppl 2:1542-52 [16247502.001]
  • [Cites] J Nutr. 2001 Dec;131(12):3189-96 [11739864.001]
  • [Cites] Am J Clin Nutr. 2002 Feb;75(2):300-7 [11815322.001]
  • [Cites] Cancer Sci. 2007 May;98(5):692-7 [17359283.001]
  • [Cites] J Cell Biol. 2007 May 21;177(4):637-45 [17502426.001]
  • [Cites] Nat Rev Microbiol. 2004 Apr;2(4):301-14 [15031729.001]
  • [Cites] Dev Cell. 2004 Apr;6(4):463-77 [15068787.001]
  • [Cites] Trends Cell Biol. 2004 Feb;14(2):70-7 [15102438.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1547-56 [15111301.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):21976-83 [15028711.001]
  • [Cites] Nature. 2004 May 20;429(6989):298-302 [15129296.001]
  • [Cites] Annu Rev Nutr. 2004;24:151-72 [15189117.001]
  • [Cites] Annu Rev Nutr. 2004;24:277-98 [15189122.001]
  • [Cites] Exp Cell Res. 2004 Aug 1;298(1):229-38 [15242777.001]
  • [Cites] J UOEH. 2004 Jun 1;26(2):193-205 [15244072.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Dec;36(12):2420-34 [15325582.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Dec;36(12):2435-44 [15325583.001]
  • [Cites] FEMS Yeast Res. 2004 Nov;5(2):101-10 [15489192.001]
  • [Cites] J Natl Cancer Inst. 1971 Jul;47(1):1-13 [4328191.001]
  • [Cites] Cancer Res. 1975 Nov;35(11 Pt. 2):3481-7 [1104155.001]
  • [Cites] Langenbecks Arch Chir. 1978 Aug 18;346(2):129-33 [682772.001]
  • [Cites] J Nutr. 1979 Nov;109(11):1847-55 [315453.001]
  • [Cites] Cancer Sci. 2008 Aug;99(8):1515-22 [18754861.001]
  • [Cites] Endocrinology. 2008 Oct;149(10):4912-20 [18583420.001]
  • [Cites] J Am Coll Nutr. 2008 Oct;27(5):577-87 [18845708.001]
  • [Cites] J Immunol. 2008 Nov 1;181(9):6491-502 [18941240.001]
  • [Cites] Biochem Soc Trans. 2008 Dec;36(Pt 6):1247-51 [19021534.001]
  • [Cites] Methods Enzymol. 2008;450:287-309 [19152866.001]
  • [Cites] Biometals. 2009 Feb;22(1):149-57 [19130267.001]
  • [Cites] Nutr Cancer. 2009;61(2):206-15 [19235036.001]
  • [Cites] Toxicol Appl Pharmacol. 2009 Mar 1;235(2):163-70 [19063910.001]
  • [Cites] Trends Mol Med. 2009 Mar;15(3):101-11 [19246244.001]
  • [Cites] Crit Care Med. 2009 Apr;37(4):1380-8 [19242332.001]
  • [Cites] J Cell Biochem. 2009 Apr 1;106(5):750-7 [19160419.001]
  • [Cites] J Mol Biol. 2009 Apr 24;388(1):144-58 [19281821.001]
  • [Cites] J Transl Med. 2009;7:17 [19292913.001]
  • [Cites] J Clin Immunol. 2009 Jul;29(4):416-25 [19408107.001]
  • [Cites] Glia. 2009 Sep;57(12):1351-61 [19229997.001]
  • [Cites] Annu Rev Nutr. 2009;29:153-76 [19400752.001]
  • (PMID = 21087493.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA 10944-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] J41CSQ7QDS / Zinc
  • [Other-IDs] NLM/ PMC3002329
  •  go-up   go-down


8. Dinan TG, Cryan J, Shanahan F, Keeling PW, Quigley EM: IBS: An epigenetic perspective. Nat Rev Gastroenterol Hepatol; 2010 08;7(8):465-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epidemiological studies of IBS point to risk factors such as familial clustering, sexual abuse and other forms of childhood trauma, low birth weight and gastrointestinal infection.
  • Studies in animal models of early stress and in humans who have experienced childhood trauma or abuse suggest that these events can lead to long-lasting epigenetic changes in the glucocorticoid receptor gene brought about by hypermethylation of a key regulatory component.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Neurol. 2008 Dec;64(6):602-17 [19107999.001]
  • [Cites] Biol Psychiatry. 2009 Feb 1;65(3):263-7 [18723164.001]
  • [Cites] World J Gastroenterol. 2008 Nov 21;14(43):6636-40 [19034965.001]
  • [Cites] PLoS One. 2008 May 07;3(5):e2085 [18461137.001]
  • [Cites] Am J Gastroenterol. 2010 Feb;105(2):275-9 [20068561.001]
  • [Cites] Gut. 2006 Dec;55(12):1754-9 [17008364.001]
  • [Cites] Schizophr Bull. 1976;2(3):360-401 [1034336.001]
  • [Cites] J Gastroenterol Hepatol. 2010 Apr;25(4):691-9 [20074154.001]
  • [Cites] Am J Clin Nutr. 2007 May;85(5):1417-27 [17490981.001]
  • [Cites] Psychosom Med. 1998 May-Jun;60(3):258-67 [9625212.001]
  • [Cites] BMC Gastroenterol. 2009 Jan 20;9:6 [19154614.001]
  • [Cites] J Trauma Stress. 2009 Oct;22(5):427-34 [19813242.001]
  • [Cites] Scand J Gastroenterol Suppl. 2003;(237):1-8 [12797672.001]
  • [Cites] J Psychiatr Res. 2008 Oct;42(13):1104-11 [18281061.001]
  • [Cites] Trends Mol Med. 2007 Jul;13(7):269-77 [17544850.001]
  • [Cites] J Clin Psychiatry. 2001;62 Suppl 8:38-45; discussion 46-7 [12108820.001]
  • [Cites] PLoS Pathog. 2008 Aug 01;4(8):e1000112 [18670628.001]
  • [Cites] Science. 2008 Mar 28;319(5871):1785-6 [18369135.001]
  • [Cites] Gut. 2003 Dec;52(12):1703-7 [14633946.001]
  • [Cites] Prog Neurobiol. 2008 Dec 11;86(4):305-41 [18940229.001]
  • [Cites] Am J Psychiatry. 1993 Oct;150(10):1502-6 [8379554.001]
  • [Cites] Eur J Hum Genet. 2007 Jul;15(7):784-90 [17457370.001]
  • [Cites] Gastroenterology. 2005 Mar;128(3):541-51 [15765388.001]
  • [Cites] Rev Endocr Metab Disord. 2007 Jun;8(2):173-82 [17638084.001]
  • [Cites] Trends Mol Med. 2009 Oct;15(10):478-89 [19811951.001]
  • [Cites] Lancet. 2001 Dec 15;358(9298):2061-8 [11755632.001]
  • [Cites] Nat Neurosci. 2009 Dec;12(12):1559-66 [19898468.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1997 Apr;9(4):345-52 [9160196.001]
  • [Cites] Hum Mol Genet. 2008 Oct 1;17 (19):2967-77 [18614545.001]
  • [Cites] Gut. 2004 Jun;53(6):829-37 [15138209.001]
  • [Cites] Gastroenterology. 2001 Oct;121(4):799-804 [11606493.001]
  • [Cites] Cell. 1993 Dec 3;75(5):843-54 [8252621.001]
  • [Cites] Gut. 2004 Oct;53(10):1452-8 [15361494.001]
  • [Cites] Gastroenterology. 2006 Feb;130(2):304-11 [16472586.001]
  • [Cites] Int J Neuropsychopharmacol. 2010 Apr;13(3):395-404 [19849891.001]
  • [Cites] Dig Dis Sci. 2009 Nov;54(11):2318-24 [19655247.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Mar 1;17(5):643-50 [12641512.001]
  • [Cites] Am J Gastroenterol. 1998 Aug;93(8):1311-7 [9707057.001]
  • [Cites] Physiol Rev. 2007 Jul;87(3):799-823 [17615389.001]
  • [Cites] Curr Opin Pediatr. 2009 Apr;21(2):243-51 [19663042.001]
  • [Cites] Am J Gastroenterol. 2005 Jun;100(6):1340-4 [15929767.001]
  • [Cites] Am J Med Genet C Semin Med Genet. 2009 May 15;151C(2):136-41 [19378334.001]
  • [Cites] Am J Gastroenterol. 2005 Mar;100(3):652-63 [15743365.001]
  • [Cites] Nat Rev Gastroenterol Hepatol. 2010 Mar;7(3):163-73 [20101257.001]
  • [Cites] Schizophr Bull. 2008 Nov;34(6):1122-9 [18703665.001]
  • [Cites] Am J Gastroenterol. 2009 Sep;104(9):2250-6 [19513027.001]
  • [Cites] PLoS One. 2009 Dec 09;4(12):e8226 [20011045.001]
  • [Cites] Mayo Clin Proc. 2000 Sep;75(9):907-12 [10994826.001]
  • [Cites] Am J Gastroenterol. 1991 Apr;86(4):417-22 [2012042.001]
  • [Cites] Neurogastroenterol Motil. 2008 Dec;20(12):1291-7 [18823288.001]
  • [Cites] Aliment Pharmacol Ther. 2009 Sep 15;30(6):643-51 [19552631.001]
  • [Cites] Nat Neurosci. 2009 Mar;12(3):342-8 [19234457.001]
  • [Cites] Dig Dis Sci. 2004 Jun;49(6):1046-53 [15309899.001]
  • [Cites] Gut. 2010 Jun;59(6):775-84 [19951903.001]
  • [Cites] Eur J Hum Genet. 2006 Feb;14(2):159-66 [16391557.001]
  • [Cites] Science. 2005 Dec 16;310(5755):1817-21 [16308420.001]
  • [Cites] J Physiol. 2004 Jul 1;558(Pt 1):263-75 [15133062.001]
  • [Cites] Gut. 1986 Jan;27(1):37-40 [3949235.001]
  • [Cites] J Pain. 2007 Dec;8(12):962-9 [17686657.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17046-9 [18955703.001]
  • [Cites] Genes Dev. 2006 Mar 1;20(5):515-24 [16510870.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Nov;3(11):1057-65 [16271334.001]
  • [Cites] J Neuroendocrinol. 2008 Jun;20(6):795-801 [18513204.001]
  • (PMID = 20585338.001).
  • [ISSN] 1759-5053
  • [Journal-full-title] Nature reviews. Gastroenterology & hepatology
  • [ISO-abbreviation] Nat Rev Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  •  go-up   go-down


9. Chappuy H, Baruchel A, Leverger G, Oudot C, Brethon B, Haouy S, Auvrignon A, Davous D, Doz F, Tréluyer JM: Parental comprehension and satisfaction in informed consent in paediatric clinical trials: a prospective study on childhood leukaemia. Arch Dis Child; 2010 Oct;95(10):800-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parental comprehension and satisfaction in informed consent in paediatric clinical trials: a prospective study on childhood leukaemia.
  • The authors included all parents whose consent was sought for their child to participate in the FRALLE 2000A protocol (acute lymphoblastic leukaemia) at two centres.
  • [MeSH-major] Health Knowledge, Attitudes, Practice. Informed Consent / psychology. Parents / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Randomized Controlled Trials as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551191.001).
  • [ISSN] 1468-2044
  • [Journal-full-title] Archives of disease in childhood
  • [ISO-abbreviation] Arch. Dis. Child.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


10. Roman-Gomez J, Jimenez-Velasco A, Barrios M, Prosper F, Heiniger A, Torres A, Agirre X: Poor prognosis in acute lymphoblastic leukemia may relate to promoter hypermethylation of cancer-related genes. Leuk Lymphoma; 2007 Jul;48(7):1269-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poor prognosis in acute lymphoblastic leukemia may relate to promoter hypermethylation of cancer-related genes.
  • The hallmark of acute lymphoblastic leukemia (ALL) is a progressive appearance of malignant cell behavior that is triggered by the evolution of altered gene function.
  • The presence in individual tumors of multiple genes simultaneously methylated is an independent factor of poor prognosis in both childhood and adult ALL in terms of disease-free survival and overall survival.
  • [MeSH-major] DNA Methylation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613754.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 100
  •  go-up   go-down


11. Costacou T, Edmundowicz D, Prince C, Conway B, Orchard TJ: Progression of coronary artery calcium in type 1 diabetes mellitus. Am J Cardiol; 2007 Nov 15;100(10):1543-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Participants in the Pittsburgh EDC Study, a prospective investigation of childhood-onset type 1 DM, who underwent 2 electron beam tomographic screenings 4 years apart were selected for study (n = 222).

  • Genetic Alliance. consumer health - Diabetes.
  • Genetic Alliance. consumer health - Diabetes mellitus type 1.
  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2004 May;182(5):1327-32 [15100140.001]
  • [Cites] Clin Chem. 1972 Jun;18(6):499-502 [4337382.001]
  • [Cites] Clin Chem. 1973 May;19(5):476-82 [4703655.001]
  • [Cites] Clin Chem. 1974 Apr;20(4):470-5 [4818200.001]
  • [Cites] Clin Chem. 1977;23(4):666-70 [66106.001]
  • [Cites] Clin Chem. 1978 Jun;24(6):900-4 [207462.001]
  • [Cites] Diabetes. 1982 Feb;31(2):136-44 [6759229.001]
  • [Cites] J Pediatr. 1985 Oct;107(4):562-4 [3930679.001]
  • [Cites] Am J Kidney Dis. 1989 Apr;13(4):321-8 [2705450.001]
  • [Cites] J Am Coll Cardiol. 1990 Mar 15;15(4):827-32 [2407762.001]
  • [Cites] Diabetes. 1990 Sep;39(9):1116-24 [2384191.001]
  • [Cites] Am J Cardiol. 1993 Aug 1;72(3):247-54 [8342500.001]
  • [Cites] Diabetologia. 2005 Jan;48(1):41-8 [15616802.001]
  • [Cites] Circulation. 2005 Feb 15;111(6):747-53 [15699257.001]
  • [Cites] Int J Biochem Cell Biol. 2006;38(5-6):996-1003 [16271309.001]
  • [Cites] Diabetologia. 2006 Aug;49(8):1946-54 [16770585.001]
  • [Cites] Diabetes. 2006 Dec;55(12):3556-65 [17130504.001]
  • [Cites] Diabetes. 2000 Apr;49(4):626-32 [10871201.001]
  • [Cites] Diabetes. 2000 Sep;49(9):1571-8 [10969842.001]
  • [Cites] AJR Am J Roentgenol. 2002 Feb;178(2):497-502 [11804925.001]
  • [Cites] Diabetes Care. 2003 Oct;26(10):2923-8 [14514603.001]
  • (PMID = 17996516.001).
  • [ISSN] 0002-9149
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK034818-23S1; United States / NIDDK NIH HHS / DK / R01 DK034818-23S1; United States / NIDDK NIH HHS / DK / DK34818; United States / NIDDK NIH HHS / DK / R37 DK034818; United States / NIDDK NIH HHS / DK / R01 DK034818
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cholesterol, HDL
  • [Other-IDs] NLM/ NIHMS34581; NLM/ PMC2206537
  •  go-up   go-down


12. Pottier N, Cheok MH, Yang W, Assem M, Tracey L, Obenauer JC, Panetta JC, Relling MV, Evans WE: Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter SNP that alters PARP1 binding and SMARCB1 expression. Hum Mol Genet; 2007 Oct 1;16(19):2261-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although cure rate of childhood acute lymphoblastic leukemia (ALL) has surpassed 80%, drug resistance remains a major cause of treatment failure.
  • Among these SNPs, the -228G>T SNP (allele frequency 9.4%) was the only one that significantly increased reporter activity in human ALL cell lines.
  • The -228G>T SNP altered SMARCB1 mRNA and protein levels and a positive association was found between the SMARCB1 mRNA level and both the -228 genotype and prednisolone sensitivity in CEPH cell lines.
  • Finally, knockdown experiments performed in human ALL cell lines confirmed that lower SMARCB1 expression increased prednisolone resistance.
  • [MeSH-minor] Amino Acid Sequence. Blotting, Western. Cell Line. Chromosome Mapping. Electrophoretic Mobility Shift Assay. Gene Frequency. Genotype. Humans. Lymphocytes / cytology. Lymphocytes / drug effects. Lymphocytes / metabolism. Molecular Sequence Data. Mutagenesis, Site-Directed. Polymorphism, Single Nucleotide. Prednisolone / pharmacology. Promoter Regions, Genetic / genetics. Protein Binding. RNA Interference. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / genetics. Sequence Alignment. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17616514.001).
  • [ISSN] 0964-6906
  • [Journal-full-title] Human molecular genetics
  • [ISO-abbreviation] Hum. Mol. Genet.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA21765; United States / NCI NIH HHS / CA / R01 CA51001; United States / NCI NIH HHS / CA / R01 CA78224; United States / NCI NIH HHS / CA / R37 CA36401; United States / NIGMS NIH HHS / GM / U01 GM61393; United States / NIGMS NIH HHS / GM / U01 GM61394
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / SMARCB1 protein, human; 0 / Steroids; 0 / Transcription Factors; 9PHQ9Y1OLM / Prednisolone; EC 2.4.2.30 / PARP1 protein, human; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
  •  go-up   go-down


13. Lan ZJ, Tang YM, Shen HQ, Qian BQ, Ning BT, Chen YH: [Evaluation of the P-gp pump function on leukemic cell membrane and proper application of its reversal agents with Calcein-AM and flow cytometry]. Zhonghua Er Ke Za Zhi; 2007 May;45(5):334-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of the P-gp pump function on leukemic cell membrane and proper application of its reversal agents with Calcein-AM and flow cytometry].
  • OBJECTIVE: Leukemia is the most common malignancy in children.
  • During the past decade, very high cure rates of childhood acute lymphoblastic leukemia (ALL) have been reported both at home and abroad.
  • However, the cure rates of children with acute myeloid leukemia (AML) remain low due to the multiple-drug resistance (MDR).
  • P-glycoprotein (P-gp) is one of the most important mechanisms of MDR for leukemia cells.
  • The present study aimed to evaluate the P-gp pump function on leukemia cell membrane and the effects of the combined administration of the reversal agents cyclosporin A (CSA) and verapamil (VER) through the observation of Calcein-AM (C-AM) metabolism in the cell line K562 and its multi-drug resistant subline K562/VCR.
  • On the other hand, significant inhibition of the efflux from the K562/VCR cell line was also noticed after the same time period of incubation with the MFIs of 2237 +/- 155, 1932 +/- 233 and 2231 +/- 147, respectively in the three groups, which was significantly higher than that of control group (1622 +/- 191, P < 0.05).
  • CSA, VER and CSA + VER could increase the uptake and inhibit the efflux of C-AM by K562/VCR cells, while no evident influence on those functions inside the parental cell line K562 cells was noticed.

  • Hazardous Substances Data Bank. VERAPAMIL HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697617.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Fluoresceins; 0 / P-Glycoprotein; 148504-34-1 / calcein AM; 5J49Q6B70F / Vincristine; CJ0O37KU29 / Verapamil; V0YM2B16TS / fluorexon
  •  go-up   go-down


14. Pan C, Gu LJ, Xue HL, Chen J, Dong L, Zhou M, Luo CY, Wang YP, Tang JY: [Evaluation of a modified induction chemotherapy in children with acute lymphoblastic leukemia]. Zhonghua Er Ke Za Zhi; 2007 May;45(5):324-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of a modified induction chemotherapy in children with acute lymphoblastic leukemia].
  • OBJECTIVE: To improve the treatment outcome of children with acute lymphoblastic leukemia (ALL), and to evaluate the efficacy and safety of a modified induction chemotherapy between the two protocols used to treat children with ALL in Shanghai Children's Medical Center.
  • 1st, 2006, 311 patients with newly diagnosed childhood ALL, who underwent induction chemotherapy for over 10 days, were eligible for analysis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphoid / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Remission Induction / methods

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697614.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Meta-Analysis
  • [Publication-country] China
  •  go-up   go-down


15. Cloppenborg T, Stanulla M, Zimmermann M, Schrappe M, Welte K, Klein C: Immunosurveillance of childhood ALL: polymorphic interferon-gamma alleles are associated with age at diagnosis and clinical risk groups. Leukemia; 2005 Jan;19(1):44-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunosurveillance of childhood ALL: polymorphic interferon-gamma alleles are associated with age at diagnosis and clinical risk groups.
  • To determine whether a CA-repeat associated with differential NFkappaB-binding and IFN-gamma-expression levels may influence the incidence, manifestation and early clinical treatment response of childhood acute lymphoblastic leukemia, we performed PCR-based genotyping of 393 patients with ALL and 207 healthy controls.
  • [MeSH-major] Interferon-gamma / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • [MeSH-minor] Cell Lineage. Child. Child, Preschool. Female. Humans. Infant. Male. Risk Factors

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15496974.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 82115-62-6 / Interferon-gamma
  •  go-up   go-down


16. Tolar J, Bostrom BC, La MK, Sather HN: Intravenous 6-mercaptopurine decreases salvage after relapse in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group study CCG 1922. Pediatr Blood Cancer; 2005 Jul;45(1):5-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravenous 6-mercaptopurine decreases salvage after relapse in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group study CCG 1922.
  • PURPOSE: To compare outcomes of patients with NCI standard risk acute lymphoblastic leukemia (ALL) who relapsed after being randomized to receive either oral or intravenous 6-mercaptopurine (6MP) in the Children's Cancer Group study CCG 1922.
  • CONCLUSION: Treatment with intravenous 6MP during a brief period of total therapy had a significant negative impact on the prognosis in childhood ALL even though oral 6MP was used during maintenance.
  • [MeSH-major] 6-Mercaptopurine / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Salvage Therapy

  • Genetic Alliance. consumer health - Childhood Cancer.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Blood Cancer. 2006 May 1;46(5):660-1 [16276523.001]
  • [CommentIn] Pediatr Blood Cancer. 2005 Jul;45(1):2-4 [15706584.001]
  • (PMID = 15481062.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-13539
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; E7WED276I5 / 6-Mercaptopurine
  •  go-up   go-down


17. Mirebeau D, Acquaviva C, Suciu S, Bertin R, Dastugue N, Robert A, Boutard P, Méchinaud F, Plouvier E, Otten J, Vilmer E, Cavé H, EORTC-CLG: The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951. Haematologica; 2006 Jul;91(7):881-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951.
  • BACKGROUND AND OBJECTIVES: Deletion and methylation of the 9p21 chromosomal region are frequent in childhood acute lymphoblastic leukemia (ALL) but the prognostic significance is controversial.
  • INTERPRETATION AND CONCLUSIONS: In this study of 227 cases of childhood B-lineage ALL, inactivation of CDKN2A, CDKN2B and MTAP did not influences the patients' outcome.
  • [MeSH-major] Gene Silencing. Neoplasm Proteins / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2006 Jul;91(7):865B [16818264.001]
  • (PMID = 16818274.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2U10CA11488-19; United States / NCI NIH HHS / CA / 5U10CA11488-35
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / CDKN2B protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


18. Chatterton Z, Morenos L, Saffery R, Craig JM, Ashley D, Wong NC: DNA methylation and miRNA expression profiling in childhood B-cell acute lymphoblastic leukemia. Epigenomics; 2010 Oct;2(5):697-708
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA methylation and miRNA expression profiling in childhood B-cell acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia (ALL) is the most common cancer in children in the modern world.
  • A number of DNA methylation and miRNA profiling studies have investigated the role of both in childhood ALL.
  • [MeSH-major] DNA Methylation / physiology. Epigenesis, Genetic / physiology. High-Throughput Screening Assays / methods. MicroRNAs / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22122053.001).
  • [ISSN] 1750-192X
  • [Journal-full-title] Epigenomics
  • [ISO-abbreviation] Epigenomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MicroRNAs
  •  go-up   go-down


19. Bastida MG, Rey RA, Bergadá I, Bedecarrás P, Andreone L, del Rey G, Boywitt A, Ropelato MG, Cassinelli H, Arcari A, Campo S, Gottlieb S: Establishment of testicular endocrine function impairment during childhood and puberty in boys with Klinefelter syndrome. Clin Endocrinol (Oxf); 2007 Dec;67(6):863-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of testicular endocrine function impairment during childhood and puberty in boys with Klinefelter syndrome.
  • OBJECTIVE: To precisely characterize the chronology of testicular endocrine function impairment during childhood and adolescence in patients with Klinefelter syndrome.
  • However, levels of the inhibin alpha-subunit precursor Pro-alphaC were in the lowest levels of the normal range in most cases.
  • CONCLUSIONS: In Klinefelter syndrome, a mild Leydig cell dysfunction is present from early childhood in most cases and persists throughout puberty.
  • Sertoli cell function is normal until mid puberty, when a dramatic impairment is observed.

  • Genetic Alliance. consumer health - Klinefelter syndrome.
  • MedlinePlus Health Information. consumer health - Klinefelter's Syndrome.
  • MedlinePlus Health Information. consumer health - Puberty.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17645574.001).
  • [ISSN] 1365-2265
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Precursors; 0 / inhibin B; 0 / inhibin-alpha subunit precursor; 3XMK78S47O / Testosterone; 57285-09-3 / Inhibins; 80497-65-0 / Anti-Mullerian Hormone; 9002-67-9 / Luteinizing Hormone
  •  go-up   go-down


20. Bessler M, Wilson DB, Mason PJ: Dyskeratosis congenita. FEBS Lett; 2010 Sep 10;584(17):3831-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With this new definition the disease spectrum has broadened and ranges from intrauterine growth retardation, cerebellar hypoplasia, and death in early childhood to asymptomatic mutation carriers whose descendants are predisposed to malignancy, BMF, or pulmonary disease.
  • [MeSH-minor] Adult. Aged. Aging / physiology. Bone Marrow / pathology. Cell Division / genetics. Genetic Diseases, Inborn / enzymology. Genetic Diseases, Inborn / genetics. Humans. Infant, Newborn. Middle Aged. Mutation. Neoplasms / epidemiology. Neoplasms / genetics. Telomerase / genetics. Telomerase / metabolism. Telomere-Binding Proteins / genetics

  • Genetic Alliance. consumer health - Dyskeratosis congenita.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
  • [Cites] Blood. 2008 Feb 1;111(3):1128-30 [18042801.001]
  • [Cites] PLoS Genet. 2008 Jan;4(1):e10 [18208333.001]
  • [Cites] Am J Hum Genet. 2008 Feb;82(2):501-9 [18252230.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jun 10;105(23):8073-8 [18523010.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10173-8 [18626023.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3594-600 [18669893.001]
  • [Cites] Blood. 2009 Jan 8;113(2):309-16 [18931339.001]
  • [Cites] Blood. 2009 Jun 25;113(26):6549-57 [19282459.001]
  • [Cites] Nat Struct Mol Biol. 2009 Jul;16(7):740-6 [19478803.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2009;10:45-61 [19405848.001]
  • [Cites] Ann N Y Acad Sci. 2009 Sep;1176:178-90 [19796246.001]
  • [Cites] Hum Mutat. 2009 Nov;30(11):1567-73 [19760749.001]
  • [Cites] PLoS One. 2009;4(11):e7926 [19936245.001]
  • [Cites] Science. 2009 Nov 13;326(5955):948-52 [19965504.001]
  • [Cites] Nat Rev Mol Cell Biol. 2010 Mar;11(3):171-81 [20125188.001]
  • [Cites] J Cell Biol. 2010 Mar 8;188(5):639-52 [20212315.001]
  • [Cites] Nucleic Acids Res. 2010 May;38(9):2955-63 [20147462.001]
  • [Cites] Hum Mol Genet. 2010 Apr 15;19(R1):R77-82 [20368264.001]
  • [Cites] Am J Hum Genet. 1994 Nov;55(5):876-82 [7977349.001]
  • [Cites] Nature. 1999 Dec 2;402(6761):551-5 [10591218.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3636-41 [7731957.001]
  • [Cites] Science. 1996 Apr 12;272(5259):258-62 [8602509.001]
  • [Cites] Dev Genet. 1996;18(2):173-9 [8934879.001]
  • [Cites] Cell. 1997 Oct 3;91(1):25-34 [9335332.001]
  • [Cites] Science. 1998 Jan 16;279(5349):349-52 [9454332.001]
  • [Cites] Nature. 1998 Apr 9;392(6676):569-74 [9560153.001]
  • [Cites] Nat Genet. 1998 May;19(1):32-8 [9590285.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):567-76 [9858580.001]
  • [Cites] Br J Haematol. 1998 Dec;103(4):990-6 [9886310.001]
  • [Cites] J Exp Med. 1999 Jul 19;190(2):157-67 [10432279.001]
  • [Cites] N Engl J Med. 2005 Apr 7;352(14):1413-24 [15814878.001]
  • [Cites] Curr Mol Med. 2005 Mar;5(2):159-70 [15974869.001]
  • [Cites] Curr Mol Med. 2005 Mar;5(2):205-11 [15974874.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1246-52 [15886322.001]
  • [Cites] Genes Dev. 2005 Sep 15;19(18):2100-10 [16166375.001]
  • [Cites] Br J Haematol. 2000 Sep;110(4):768-79 [11054058.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):677-85 [11257099.001]
  • [Cites] Blood Cells Mol Dis. 2001 Mar-Apr;27(2):353-7 [11259155.001]
  • [Cites] Nature. 2001 Sep 27;413(6854):432-5 [11574891.001]
  • [Cites] Lancet. 2002 Jun 22;359(9324):2168-70 [12090986.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):497-501 [12640452.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2003 Mar;17(2):216-8 [12705757.001]
  • [Cites] Nat Genet. 2004 May;36(5):447-9 [15098033.001]
  • [Cites] Annu Rev Biochem. 2004;73:177-208 [15189140.001]
  • [Cites] Cell. 1987 Dec 24;51(6):887-98 [3319189.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Sep;85(18):6622-6 [3413114.001]
  • [Cites] Cell. 1989 Nov 3;59(3):521-9 [2805070.001]
  • [Cites] Mol Cell Biol. 1990 Feb;10(2):518-27 [2300052.001]
  • [Cites] Nature. 1990 May 31;345(6274):458-60 [2342578.001]
  • [Cites] Nature. 1990 Aug 30;346(6287):866-8 [2392154.001]
  • [Cites] Nature. 1991 Apr 18;350(6319):569-73 [1708110.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10114-8 [1438199.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15960-4 [16247010.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17119-24 [16284252.001]
  • [Cites] Mol Cell. 2006 Jan 20;21(2):249-60 [16427014.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2680-5 [16332973.001]
  • [Cites] Cell Death Differ. 2006 Jun;13(6):927-34 [16543935.001]
  • [Cites] Nature. 2006 Sep 21;443(7109):302-7 [16943774.001]
  • [Cites] Semin Neurol. 2007 Apr;27(2):143-50 [17390259.001]
  • [Cites] N Engl J Med. 2007 Mar 29;356(13):1317-26 [17392301.001]
  • [Cites] Science. 2007 Mar 30;315(5820):1850-3 [17395830.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 1;104(18):7552-7 [17460043.001]
  • [Cites] Hum Mol Genet. 2007 Jul 1;16(13):1619-29 [17507419.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1013-20 [17640862.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1439-47 [17468339.001]
  • [Cites] Aging Cell. 2007 Oct;6(5):689-97 [17875000.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4198-205 [17785587.001]
  • [Cites] Biochimie. 2008 Jan;90(1):122-30 [17825470.001]
  • [Cites] Mol Cell. 2007 Dec 14;28(5):773-85 [18082603.001]
  • (PMID = 20493861.001).
  • [ISSN] 1873-3468
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA105312; United States / NCI NIH HHS / CA / R01 CA106995; United States / NCI NIH HHS / CA / R01 CA106995; United States / NCI NIH HHS / CA / R01 CA106995-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Telomere-Binding Proteins; 0 / shelterin, human; EC 2.7.7.49 / Telomerase
  • [Other-IDs] NLM/ NIHMS300709; NLM/ PMC3238451
  •  go-up   go-down


21. Franchini C, Fontana F, Minuzzo M, Babbio F, Privitera E: Apoptosis promoted by up-regulation of TFPT (TCF3 fusion partner) appears p53 independent, cell type restricted and cell density influenced. Apoptosis; 2006 Dec;11(12):2217-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptosis promoted by up-regulation of TFPT (TCF3 fusion partner) appears p53 independent, cell type restricted and cell density influenced.
  • The TFPT/FB1 gene was identified because of its involvement in childhood pre-B acute lymphoblastic leukaemia (ALL).
  • Although its specific function is still unclear, Tfpt has been implicated in cell proliferation and induction of programmed cell death (PCD).
  • Given the critical role of PCD in leukemogenesis, we have investigated the responsiveness of different cell lines to TFPT over expression and the consequent induction of PCD by proliferation kinetic analysis, immunolocalization and TUNEL assay.
  • We have also tested the involvement of factors implicated in cell cycle progression and apoptosis, i.e. caspases, p53, Cdc2.
  • Our results indicate that over expression of TFPT promotes caspase 9-dependent apoptosis, nevertheless the apoptotic cascade is engaged only in culture conditions sustaining cell proliferation and different cell lines display differential responsiveness to TFPT induced apoptosis Although p53 is a main regulator of apoptosis in mammalian cells, the Tfpt induced apoptosis appears p53-independent.
  • [MeSH-minor] Animals. Caspases / metabolism. Cell Count. Cell Proliferation. Enzyme Activation. Gene Expression. HeLa Cells. Humans. In Situ Nick-End Labeling. Kinetics. Mice. Models, Biological. NIH 3T3 Cells. Protein Binding. Transcription Factor 7-Like 1 Protein

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17041757.001).
  • [ISSN] 1360-8185
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / TCF Transcription Factors; 0 / TCF7L1 protein, human; 0 / TFPT protein, human; 0 / TFPT protein, mouse; 0 / Tcf7l1 protein, mouse; 0 / Transcription Factor 7-Like 1 Protein; 0 / Tumor Suppressor Protein p53; EC 3.4.22.- / Caspases
  •  go-up   go-down


22. Ociepa T, Maloney E, Kamieńska E, Wysocki M, Kurylak A, Matysiak M, Urasiński T, Urasińska E, Domagała W: Simultaneous assessment of p53 and MDM2 expression in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukemia. Pol J Pathol; 2010;61(4):199-205
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous assessment of p53 and MDM2 expression in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukemia.
  • Ineffective apoptosis is one of main causes of a treatment failure in childhood acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Leukocytes, Mononuclear / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Prednisone / therapeutic use. Proto-Oncogene Proteins c-mdm2 / metabolism. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21290342.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2; VB0R961HZT / Prednisone
  •  go-up   go-down


23. Anuchapreeda S, Thanarattanakorn P, Sittipreechacharn S, Tima S, Chanarat P, Limtrakul P: Inhibitory effect of curcumin on MDR1 gene expression in patient leukemic cells. Arch Pharm Res; 2006 Oct;29(10):866-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The leukemic cells were collected from 78 childhood leukemia patients admitted at Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand, in the period from July 2003 to February 2005.
  • There were 61 cases of acute lymphoblastic leukemia (ALL), 14 cases of acute myeloblastic leukemia (AML), and 3 cases of chronic myelocytic leukemia (CML).
  • Thus, curcumin treatment may provide a lead for clinical treatment of leukemia patients in the future.
  • [MeSH-minor] Acute Disease. Adolescent. Age Factors. Antineoplastic Agents / chemistry. Antineoplastic Agents / pharmacology. Bone Marrow / drug effects. Bone Marrow / metabolism. Bone Marrow / pathology. Cell Survival / drug effects. Child, Preschool. Female. Humans. Infant. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Leukemia, Myeloid / blood. Leukemia, Myeloid / genetics. Leukemia, Myeloid / pathology. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. RNA, Messenger / genetics. RNA, Messenger / isolation & purification. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. CURCUMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17121181.001).
  • [ISSN] 0253-6269
  • [Journal-full-title] Archives of pharmacal research
  • [ISO-abbreviation] Arch. Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Messenger; IT942ZTH98 / Curcumin
  •  go-up   go-down


24. Hundsdoerfer P, Dietrich I, Schmelz K, Eckert C, Henze G: XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL. Pediatr Blood Cancer; 2010 Aug;55(2):260-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL.
  • BACKGROUND: Resistance to glucocorticoid induced apoptosis is one of the major risk factors for relapse and poor outcome in childhood acute lymphoblastic leukemia (ALL).
  • PROCEDURE: XIAP protein and mRNA expression were determined in leukemic blasts of 51 childhood ALL patients and normal bone marrow mononuclear cells.
  • RESULTS: XIAP protein but not mRNA expression was found to be highly increased in childhood ALL compared to control bone marrow mononuclear cells (MNC) (median: 3.5 vs. 0.14 ng/10(5) MNC, P < 0.0001) indicating a post-transcriptional regulation of XIAP expression.
  • In patients with T-cell ALL, poor prednisone response was associated with increased XIAP expression (median: 2.8 in good vs. 5.8 in poor responders; P = 0.005).
  • Similarly, T-cell ALL patients suffering adverse events showed higher initial XIAP levels than patients in continuous complete remission (CCR) (median: 2.7 in patients in CCR vs. 5.6 in patients suffering adverse events; P = 0.007).
  • CONCLUSION: In childhood ALL compared to control bone marrow, the expression of the apoptosis inhibitor XIAP is highly increased by post-transcriptional regulation.
  • The association with poor in vivo glucocorticoid response and outcome in T-cell ALL suggests XIAP inhibition as a promising novel approach for the treatment of resistant ALL.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Glucocorticoids / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. X-Linked Inhibitor of Apoptosis Protein / genetics
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Bone Marrow Cells / pathology. Bone Marrow Examination. Child. Drug Resistance. Female. Humans. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Male. Monocytes / pathology. Pharmacogenetics. Prognosis. RNA, Messenger / analysis. Treatment Outcome. Up-Regulation


25. McLaughlin CC, Baptiste MS, Schymura MJ, Nasca PC, Zdeb MS: Birth weight, maternal weight and childhood leukaemia. Br J Cancer; 2006 Jun 5;94(11):1738-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Birth weight, maternal weight and childhood leukaemia.
  • There is mounting evidence that childhood leukaemia is associated with high birth weight, but few studies have examined the relationship between leukaemia and other perinatal factors that influence birth weight, such as maternal weight or gestational weight gain.
  • This case-cohort study included 916 acute lymphocytic leukaemia (ALL) and 154 acute myeloid leukaemia (AML) cases diagnosed prior to age 10 years between 1985 and 2001 and born in New York State excluding New York City between 1978 and 2001.
  • These findings suggest childhood leukaemia may be related to factors influencing abnormal fetal growth patterns.

  • MedlinePlus Health Information. consumer health - Birth Weight.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):356-61 [11875699.001]
  • [Cites] Cancer Causes Control. 2002 Feb;13(1):15-25 [11899114.001]
  • [Cites] Am J Epidemiol. 2002 Apr 1;155(7):603-13 [11914187.001]
  • [Cites] Cancer Causes Control. 2002 Sep;13(7):595-602 [12296506.001]
  • [Cites] Am J Obstet Gynecol. 2003 May;188(5):1372-8 [12748514.001]
  • [Cites] Obstet Gynecol. 2003 Jul;102(1):115-20 [12850616.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2321-33 [12791663.001]
  • [Cites] J Community Health. 2003 Oct;28(5):335-46 [14535599.001]
  • [Cites] Am J Epidemiol. 2003 Oct 15;158(8):724-35 [14561661.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):139-45 [14710221.001]
  • [Cites] Int J Cancer. 2004 Jun 20;110(3):465-7 [15095317.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):1057-64 [15184264.001]
  • [Cites] Am J Obstet Gynecol. 2004 Sep;191(3):964-8 [15467573.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 20;96(20):1549-56 [15494605.001]
  • [Cites] J Natl Cancer Inst. 1969 May;42(5):857-66 [5254278.001]
  • [Cites] J Natl Cancer Inst. 1971 Sep;47(3):501-9 [5157573.001]
  • [Cites] Int J Cancer. 1975 Jun 15;15(6):941-6 [1150348.001]
  • [Cites] J Natl Cancer Inst. 1976 May;56(5):879-83 [994200.001]
  • [Cites] Am J Epidemiol. 1984 May;119(5):788-95 [6720675.001]
  • [Cites] Int J Epidemiol. 1985 Dec;14(4):555-9 [3866751.001]
  • [Cites] Arch Dis Child. 1987 Mar;62(3):279-87 [3646026.001]
  • [Cites] Cancer. 1988 Aug 1;62(3):635-44 [3164642.001]
  • [Cites] Lancet. 1988 Dec 10;2(8624):1323-7 [2904050.001]
  • [Cites] Cancer Res. 1991 Jul 15;51(14):3696-701 [2065325.001]
  • [Cites] Cancer. 1991 Sep 15;68(6):1351-5 [1873786.001]
  • [Cites] Leukemia. 1994 May;8(5):856-64 [8182942.001]
  • [Cites] Br J Cancer. 1994 Sep;70(3):531-6 [8080742.001]
  • [Cites] Pediatr Hematol Oncol. 1994 Nov-Dec;11(6):587-99 [7857782.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 21;87(12):908-14 [7666480.001]
  • [Cites] Cancer Causes Control. 1996 Sep;7(5):553-9 [8877054.001]
  • [Cites] Ann Epidemiol. 1997 Apr;7(3):172-9 [9141639.001]
  • [Cites] BMJ. 1997 May 10;314(7091):1376-80 [9161309.001]
  • [Cites] J Natl Cancer Inst. 1997 Jul 2;89(13):939-47 [9214673.001]
  • [Cites] Br J Cancer. 1997;76(3):406-15 [9252212.001]
  • [Cites] Br J Cancer. 1997;76(9):1241-7 [9365177.001]
  • [Cites] J Pediatr. 1997 Nov;131(5):671-7 [9403644.001]
  • [Cites] J Pediatr. 1999 Feb;134(2):178-84 [9931526.001]
  • [Cites] Cancer Causes Control. 1999 Feb;10(1):85-94 [10334647.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1483-9 [10424755.001]
  • [Cites] Br J Cancer. 1999 Aug;80(11):1844-51 [10468308.001]
  • [Cites] J Natl Cancer Inst. 1957 Dec;19(6):1087-94 [13502763.001]
  • [Cites] Pediatrics. 2005 Mar;115(3):e290-6 [15741354.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1457-67 [15712273.001]
  • [Cites] Cancer Causes Control. 2005 Nov;16(9):1075-83 [16184473.001]
  • [Cites] Eur J Endocrinol. 2005 Dec;153(6):887-94 [16322395.001]
  • [Cites] Pediatr Hematol Oncol. 1987;4(1):63-72 [3152913.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 20;91(20):1765-72 [10528028.001]
  • [Cites] Int J Cancer. 1999 Dec 10;83(6):712-7 [10597183.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):486-8 [11054681.001]
  • [Cites] Am J Epidemiol. 2001 Nov 15;154(10):889-90 [11700241.001]
  • [Cites] Lancet. 2001 Dec 8;358(9297):1935-40 [11747917.001]
  • [Cites] Coll Antropol. 2001 Dec;25(2):535-43 [11811284.001]
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1428-37 [11821358.001]
  • [Cites] Epidemiology. 1999 May;10(3):271-5 [10230837.001]
  • (PMID = 16736025.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / PHS HHS / / U55/CCU222012-03
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361297
  •  go-up   go-down


26. Gualco G, Chioato L, Weiss LM, Harrington WJ Jr, Bacchi CE: Analysis of human T-cell lymphotropic virus in CD25+ anaplastic large cell lymphoma in children. Am J Clin Pathol; 2009 Jul;132(1):28-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of human T-cell lymphotropic virus in CD25+ anaplastic large cell lymphoma in children.
  • Anaplastic large cell lymphoma (ALCL) is recognized as 2 distinct diseases: anaplastic lymphoma kinase (ALK)+ ALCL and ALK- ALCL.
  • Human T-cell lymphotropic virus (HTLV-1) is linked to the development of adult T-cell leukemia/lymphoma (ATLL), which frequently expresses CD25.
  • CD25 is significantly expressed in childhood ALCL.
  • We analyzed 33 cases of pediatric ALCL, CD25+ and CD25-, for proviral HTLV-1 DNA.

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatrics. 2003 Aug;112(2):e136-42 [12897319.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5587-94 [15328201.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Leukemia. 1994 Mar;8(3):507-9 [8127156.001]
  • [Cites] Hum Pathol. 1995 Jun;26(6):614-9 [7774890.001]
  • [Cites] Mod Pathol. 1996 Jan;9(1):63-7 [8821959.001]
  • [Cites] Histol Histopathol. 1997 Jul;12(3):595-601 [9225139.001]
  • [Cites] Am J Pathol. 1998 Mar;152(3):683-9 [9502410.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] Hum Pathol. 2008 Oct;39(10):1505-10 [18620733.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 May 1;21(1):65-71 [10235516.001]
  • [Cites] Blood. 1999 May 1;93(9):3088-95 [10216106.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4624-33 [15735688.001]
  • [Cites] J Virol. 2005 Sep;79(18):11925-34 [16140768.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):575-83 [16410787.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):690-2 [16410788.001]
  • [Cites] Haematologica. 2006 May;91(5):596-604 [16670065.001]
  • [Cites] J Pediatr (Rio J). 2006 Nov-Dec;82(6):411-20 [17171202.001]
  • [Cites] Am J Clin Pathol. 2007 May;127(5):707-22 [17511113.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3699-703 [17530023.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2259-67 [17519389.001]
  • [Cites] Am J Clin Pathol. 2007 Nov;128(5):875-82 [17951212.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2007;:285-96 [18024642.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1560-6 [17957029.001]
  • [Cites] Pediatr Blood Cancer. 2008 Apr;50(4):784-7 [18022899.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1830-5 [11920547.001]
  • [Cites] Am J Hematol. 2001 Jul;67(3):172-8 [11391714.001]
  • [Cites] Best Pract Res Clin Haematol. 2003 Mar;16(1):117-33 [12670470.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):823-35 [12131150.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3355-7 [15205267.001]
  • (PMID = 19864230.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112217-03; United States / NCI NIH HHS / CA / CA121935-03; United States / NCI NIH HHS / CA / R01 CA112217-03; United States / NCI NIH HHS / CA / R01 CA082274-08; United States / NCI NIH HHS / CA / R01 CA082274; United States / NCI NIH HHS / CA / R01 CA121935-03; United States / NCI NIH HHS / CA / R01 CA121935
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / IL2RA protein, human; 0 / Interleukin-2 Receptor alpha Subunit; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ NIHMS125676; NLM/ PMC2771325
  •  go-up   go-down


27. Anuradha B, Santosh CM, Hari Sai Priya V, Suman Latha G, Murthy KJ, Vijaya Lakshmi V: Age-related waning of in vitro Interferon-gamma levels against r32kDaBCG in BCG vaccinated children. J Immune Based Ther Vaccines; 2007;5:8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nevertheless, it significantly reduces the risk of severe childhood tuberculosis and continues to be used to prevent tuberculosis in many countries.
  • CD3+, CD4+ and CD8+ cell counts were measured by Flow cytometry. r32kDaBCG (Ag85A-BCG) protein was used to stimulate T cells in in vitro T cell responses and interferon-gamma (IFN-gamma) cytokine levels in the supernatants were measured by ELISA.
  • T cell subsets were within the normal range in all subjects.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • [Cites] Bull World Health Organ. 1974;51(5):473-88 [4549498.001]
  • [Cites] Infect Immun. 1994 Sep;62(9):3679-87 [7520418.001]
  • [Cites] Infect Immun. 1994 Dec;62(12):5319-26 [7525483.001]
  • [Cites] J Immunol. 1995 May 1;154(9):4665-74 [7722319.001]
  • [Cites] Indian Pediatr. 1993 Jul;30(7):899-903 [8132282.001]
  • [Cites] Infect Immun. 1994 Feb;62(2):726-8 [8300233.001]
  • [Cites] Int J Epidemiol. 1995 Oct;24(5):1042-9 [8557438.001]
  • [Cites] Immunology. 1996 Mar;87(3):339-42 [8778016.001]
  • [Cites] J Infect Dis. 1997 Nov;176(5):1351-9 [9359738.001]
  • [Cites] Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):679-91 [9517576.001]
  • [Cites] Infect Immun. 1998 Nov;66(11):5537-42 [9784569.001]
  • [Cites] Infect Immun. 2000 Dec;68(12):7144-8 [11083843.001]
  • [Cites] Infect Immun. 2001 Apr;69(4):2714-7 [11254639.001]
  • [Cites] J Immunol. 2001 Nov 1;167(9):5217-25 [11673535.001]
  • [Cites] Science. 2002 Jan 11;295(5553):338-42 [11786644.001]
  • [Cites] Indian Pediatr. 2002 Jan;39(1):70-4 [11805356.001]
  • [Cites] Immunology. 2002 Mar;105(3):314-24 [11918693.001]
  • [Cites] Indian Pediatr. 2002 Apr;39(4):362-5 [11976465.001]
  • [Cites] Infect Immun. 2003 Jan;71(1):483-93 [12496199.001]
  • [Cites] Immunol Cell Biol. 2003 Feb;81(1):34-45 [12534944.001]
  • [Cites] Ann Clin Microbiol Antimicrob. 2004 Jun 3;3:10 [15176980.001]
  • [Cites] Scand J Immunol. 2004 Sep;60(3):273-7 [15320884.001]
  • [Cites] Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):89-93 [15687032.001]
  • [Cites] Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):107-14 [15687034.001]
  • [Cites] Indian Pediatr. 2005 Jan;42(1):36-40 [15695856.001]
  • [Cites] Infect Immun. 1992 Jul;60(7):2880-6 [1612754.001]
  • [Cites] Clin Microbiol Rev. 2005 Oct;18(4):687-702 [16223953.001]
  • [Cites] Thorax. 2006 Mar;61(3):247-9 [16384882.001]
  • [Cites] Lancet Infect Dis. 2006 Aug;6(8):522-8 [16870530.001]
  • [Cites] Nature. 1991 Sep 12;353(6340):180-4 [1832488.001]
  • [Cites] Tubercle. 1987 Mar;68(1):33-8 [3660460.001]
  • [Cites] Clin Diagn Lab Immunol. 1994 May;1(3):261-8 [7496960.001]
  • (PMID = 17555578.001).
  • [ISSN] 1476-8518
  • [Journal-full-title] Journal of immune based therapies and vaccines
  • [ISO-abbreviation] J Immune Based Ther Vaccines
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1899498
  •  go-up   go-down


28. Efferth T, Gillet JP, Sauerbrey A, Zintl F, Bertholet V, de Longueville F, Remacle J, Steinbach D: Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia. Mol Cancer Ther; 2006 Aug;5(8):1986-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia.
  • A major issue in the treatment of T-cell acute lymphoblastic leukemia (T-ALL) is resistance to chemotherapeutic drugs.
  • [MeSH-major] ATP-Binding Cassette Transporters / genetics. Drug Resistance, Neoplasm / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16928819.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCA2 protein, human; 0 / ABCA3 protein, human; 0 / ATP-Binding Cassette Transporters; 0 / Antineoplastic Agents; 0 / Multidrug Resistance-Associated Proteins
  •  go-up   go-down


29. Rudant J, Menegaux F, Leverger G, Baruchel A, Lambilliotte A, Bertrand Y, Patte C, Pacquement H, Vérité C, Robert A, Michel G, Margueritte G, Gandemer V, Hémon D, Clavel J: Childhood hematopoietic malignancies and parental use of tobacco and alcohol: the ESCALE study (SFCE). Cancer Causes Control; 2008 Dec;19(10):1277-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood hematopoietic malignancies and parental use of tobacco and alcohol: the ESCALE study (SFCE).
  • OBJECTIVES: Investigating the role of parental smoking and maternal alcohol consumption in the etiology of childhood hematopoietic malignancies.
  • RESULTS: A total of 765 cases of acute leukemia (AL), 130 of Hodgkin's lymphoma (HL), 165 of non-Hodgkin's lymphoma (NHL) and 1681 controls were included.
  • Paternal smoking was significantly associated with childhood ALL (OR = 1.4 [1.1-1.7]), AML (OR = 1.5 [1.0-2.3]), Burkitt (OR = 2.0 [1.2-3.2]), and anaplastic large cell (OR = 3.2 [1.2-9.1]) NHL.
  • CONCLUSION: The results support the hypothesis that only paternal smoking, and not maternal alcohol consumption or cigarette smoking, plays a role in childhood hematopoietic malignancies.
  • [MeSH-minor] Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / pathology. Case-Control Studies. Child. Child, Preschool. Female. France / epidemiology. Hodgkin Disease / epidemiology. Hodgkin Disease / pathology. Humans. Incidence. Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / pathology. Logistic Models. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology. Male. Maternal Exposure / adverse effects. Odds Ratio. Paternal Exposure / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Pregnancy. Registries / statistics & numerical data. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Alcohol.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18618277.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


30. Meleshko AN, Lipay NV, Stasevich IV, Potapnev MP: Rearrangements of IgH, TCRD and TCRG genes as clonality marker of childhood acute lymphoblastic leukemia. Exp Oncol; 2005 Dec;27(4):319-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rearrangements of IgH, TCRD and TCRG genes as clonality marker of childhood acute lymphoblastic leukemia.
  • AIM: Immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements are excellent patient-specific targets for clonality studies and monitoring of acute lymphoblastic leukemia (ALL).
  • RESULTS: TCRD gene rearrangements were detected in 64%, TCRG - in 45%, and IgH - in 79% of B-precursor ALL patients.
  • The highest incidence of oligoclonal rearrangements - 25% was shown for IgH gene in patients with B-precursor ALL.
  • Seven pair cases of patients with de novo leukemia and relapses were analyzed and revealed subclonal deviation in rearrangements of IgH or TCR genes during disease evolution.
  • CONCLUSION: We propose a panel of 13 types of rearrangements (primer pairs) sufficient for tumor cell clonality detection in 96% of patients with ALL.
  • [MeSH-major] Gene Rearrangement, B-Lymphocyte, Heavy Chain. Gene Rearrangement, delta-Chain T-Cell Antigen Receptor. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


31. Kelly DF, Snape MD, Perrett KP, Clutterbuck EA, Lewis S, Blanchard Rohner G, Jones M, Yu LM, Pollard AJ: Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine. Immunology; 2009 May;127(1):134-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine.
  • The induction of persistent protective levels of pathogen-specific antibody is an important goal of immunization against childhood infections.
  • An essential prelude to larger studies of peripheral blood B cells is an understanding of B-cell kinetics following immunization.
  • We measured MenC- and diphtheria-specific plasma and memory B-cell kinetics in infants receiving a CRM(197) (cross-reactive material; mutant diphtheria toxoid)-conjugated MenC vaccine at 2, 3 and 4 months of age.
  • Plasma cell responses were more delayed after the first dose when compared with the rapid appearance of plasma cells after the third dose.
  • This study provides data on B-cell kinetics following a primary schedule of immunization in young infants upon which to base further studies of the underlying cellular mechanism of humoral immunity.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Immunol. 2005;23:487-513 [15771579.001]
  • [Cites] J Immunol. 2006 Jan 1;176(1):165-72 [16365407.001]
  • [Cites] JAMA. 2005 Dec 21;294(23):3019-23 [16414950.001]
  • [Cites] J Infect Dis. 2006 Mar 15;193(6):821-8 [16479517.001]
  • [Cites] J Immunol. 2006 Apr 1;176(7):4042-50 [16547239.001]
  • [Cites] J Med Microbiol. 2006 Jul;55(Pt 7):887-96 [16772416.001]
  • [Cites] Immunol Rev. 2006 Jun;211:303-9 [16824137.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2642-7 [16675705.001]
  • [Cites] JAMA. 2000 Jun 7;283(21):2795-801 [10838647.001]
  • [Cites] Eur J Immunol. 2001 Mar;31(3):939-46 [11241299.001]
  • [Cites] Vaccine. 2001 Nov 12;20(3-4):498-504 [11672915.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2154-61 [11877292.001]
  • [Cites] J Immunol. 2002 Oct 15;169(8):4213-21 [12370351.001]
  • [Cites] Science. 2002 Dec 13;298(5601):2199-202 [12481138.001]
  • [Cites] Nature. 2003 Jan 16;421(6920):282-7 [12529646.001]
  • [Cites] Vaccine. 2003 Jun 1;21 Suppl 2:S35-7 [12763680.001]
  • [Cites] Arthritis Rheum. 2003 Aug;48(8):2146-54 [12905467.001]
  • [Cites] Infect Immun. 2003 Oct;71(10):5549-55 [14500473.001]
  • [Cites] J Immunol. 2003 Nov 15;171(10):4969-73 [14607890.001]
  • [Cites] J Clin Immunol. 2003 Nov;23(6):528-38 [15031640.001]
  • [Cites] J Immunol Methods. 2004 Mar;286(1-2):111-22 [15087226.001]
  • [Cites] Semin Immunol. 2004 Jun;16(3):197-203 [15130504.001]
  • [Cites] N Engl J Med. 2004 Jun 17;350(25):2572-81 [15201414.001]
  • [Cites] Lancet. 2004 Jul 24-30;364(9431):365-7 [15276396.001]
  • [Cites] Clin Exp Immunol. 1970 Apr;6(4):473-91 [4320164.001]
  • [Cites] Scand J Infect Dis. 1977;9(2):105-10 [408918.001]
  • [Cites] Clin Exp Immunol. 1978 Jun;32(3):443-50 [80296.001]
  • [Cites] J Immunol. 1979 Jun;122(6):2498-504 [312871.001]
  • [Cites] Clin Immunol Immunopathol. 1981 May;19(2):196-205 [6971719.001]
  • [Cites] J Immunol. 1982 Feb;128(2):639-43 [6976383.001]
  • [Cites] J Clin Immunol. 1981 Jul;1(3):174-80 [6801082.001]
  • [Cites] J Clin Invest. 1983 Apr;71(4):1032-40 [6339558.001]
  • [Cites] J Clin Invest. 1984 May;73(5):1377-84 [6609170.001]
  • [Cites] Eur J Immunol. 1991 Dec;21(12):2951-62 [1748148.001]
  • [Cites] J Exp Med. 2005 Feb 21;201(4):545-54 [15710653.001]
  • [Cites] Clin Infect Dis. 2006 Dec 1;43(11):1387-94 [17083009.001]
  • [Cites] N Engl J Med. 2007 Nov 8;357(19):1903-15 [17989383.001]
  • [Cites] J Immunol. 2008 Feb 15;180(4):2165-73 [18250423.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4802-7 [18339801.001]
  • [Cites] Annu Rev Immunol. 1994;12:117-39 [8011279.001]
  • [Cites] J Clin Microbiol. 1994 Jun;32(6):1475-82 [8077392.001]
  • [Cites] J Virol. 1995 Mar;69(3):1895-902 [7853531.001]
  • [Cites] Eur J Immunol. 1996 Feb;26(2):444-8 [8617316.001]
  • [Cites] J Immunol. 1996 Oct 15;157(8):3357-65 [8871632.001]
  • [Cites] Ann N Y Acad Sci. 1996 Oct 25;797:166-76 [8993360.001]
  • [Cites] Nature. 1997 Jul 10;388(6638):133-4 [9217150.001]
  • [Cites] J Immunol. 1997 Sep 15;159(6):2652-7 [9300684.001]
  • [Cites] J Exp Med. 1998 Mar 16;187(6):885-95 [9500791.001]
  • [Cites] Immunity. 1998 Mar;8(3):363-72 [9529153.001]
  • [Cites] J Infect Dis. 1999 Jun;179(6):1569-72 [10228085.001]
  • [Cites] J Immunol. 1999 Oct 15;163(8):4315-27 [10510371.001]
  • [Cites] Pediatr Infect Dis J. 2004 Dec;23(12 Suppl):S274-9 [15597069.001]
  • [Cites] Lancet Infect Dis. 2005 Jan;5(1):21-30 [15620558.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1614-21 [15507523.001]
  • [ErratumIn] Immunology. 2011 Apr;132(4):589
  • (PMID = 19175802.001).
  • [ISSN] 1365-2567
  • [Journal-full-title] Immunology
  • [ISO-abbreviation] Immunology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Meningococcal Vaccines; 0 / Vaccines, Conjugate; 0 / serogroup C meningococcal conjugate vaccine; 08VC9WC084 / CRM197 (non-toxic variant of diphtheria toxin)
  • [Other-IDs] NLM/ PMC2678189
  •  go-up   go-down


32. Youngs RM, Chu MS, Meloni EG, Naydenov A, Carlezon WA Jr, Konradi C: Lithium administration to preadolescent rats causes long-lasting increases in anxiety-like behavior and has molecular consequences. J Neurosci; 2006 May 31;26(22):6031-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because the symptoms of BPD in children are different from the typical symptoms in adulthood and have significant overlap with other childhood psychiatric disorders, this disorder is notoriously difficult to diagnose.

  • Genetic Alliance. consumer health - Anxiety.
  • MedlinePlus Health Information. consumer health - Anxiety.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LITHIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16738246.001).
  • [ISSN] 1529-2401
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / R01 MH063266; United States / NIMH NIH HHS / MH / MH63266; United States / NIMH NIH HHS / MH / R01 MH074000-01A1; United States / NIMH NIH HHS / MH / R01 MH074000; United States / NIMH NIH HHS / MH / MH074000-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 63231-63-0 / RNA; 9FN79X2M3F / Lithium
  • [Other-IDs] NLM/ NIHMS197434; NLM/ PMC4205587
  •  go-up   go-down


33. Braoudaki M, Karpusas M, Katsibardi K, Papathanassiou Ch, Karamolegou K, Tzortzatou-Stathopoulou F: Frequency of FLT3 mutations in childhood acute lymphoblastic leukemia. Med Oncol; 2009 Dec;26(4):460-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of FLT3 mutations in childhood acute lymphoblastic leukemia.
  • FLT3 mutations are occasionally observed in acute lymphoblastic leukemia (ALL).
  • This study investigated the incidence of FLT3 mutations in 86 pediatric patients diagnosed with ALL and the co-presence of common RAS mutations.
  • [MeSH-major] Mutation / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. fms-Like Tyrosine Kinase 3 / genetics


34. Chen FX, Cui YQ, Wu ZL, Ye TZ, Lai YH, Zou YW, Lu CY, Guan JM, Wei FG, Zhang H: [Research on the pharmacokinetics and pharmacodynamics of L-asparaginase during its treatment of childhood acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2005 Feb;26(2):100-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Research on the pharmacokinetics and pharmacodynamics of L-asparaginase during its treatment of childhood acute lymphoblastic leukemia].
  • OBJECTIVE: To investigate the changes in the activity of Escherichia coli asparaginase (L-asp) and the concentration of asparagines (ASN) in the plasma of the acute lymphoblastic leukemia (ALL) children receiving L-asp containing chemotherapeutic protocol to explore more reasonable usage of L-asp in the treatment of childhood ALL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Asparaginase / pharmacokinetics. Asparagine / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. ASPARAGINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15921627.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 7006-34-0 / Asparagine; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


35. Fronkova E, Madzo J, Zuna J, Reznickova L, Muzikova K, Hrusak O, Stary J, Trka J: TEL/AML 1 real-time quantitative reverse transcriptase PCR can complement minimal residual disease assessment in childhood ALL. Leukemia; 2005 Jul;19(7):1296-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TEL/AML 1 real-time quantitative reverse transcriptase PCR can complement minimal residual disease assessment in childhood ALL.
  • [MeSH-major] Neoplasm, Residual / diagnosis. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Reverse Transcriptase Polymerase Chain Reaction / methods
  • [MeSH-minor] Child. Core Binding Factor Alpha 2 Subunit. Humans. Immunoglobulins / genetics. Prospective Studies. Receptors, Antigen, T-Cell / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15858617.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Immunoglobulins; 0 / Oncogene Proteins, Fusion; 0 / Receptors, Antigen, T-Cell; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


36. Rosenthal LA: Animal models of virus-induced chronic airway disease. Immunol Allergy Clin North Am; 2010 Nov;30(4):497-511, vi
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Investigation of these rodent models should complement the research from pediatric cohort studies and begin to bring us closer to understanding the role of viral respiratory tract infections in the inception of childhood asthma.

  • MedlinePlus Health Information. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Viral Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] Pediatr Infect Dis J. 2008 Oct;27(10 Suppl):S60-2 [18820580.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Oct 1;178(7):667-72 [18565953.001]
  • [Cites] J Virol. 2009 May;83(9):4185-94 [19211758.001]
  • [Cites] Int J Exp Pathol. 2009 Aug;90(4):431-8 [19659901.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2009 Sep;297(3):L401-10 [19561139.001]
  • [Cites] Virol J. 2009;6:122 [19671179.001]
  • [Cites] Proc Am Thorac Soc. 2009 Dec;6(8):693-6 [20008877.001]
  • [Cites] J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S95-102 [20176271.001]
  • [Cites] J Allergy Clin Immunol. 2010 Jun;125(6):1202-5 [20304476.001]
  • [Cites] J Allergy Clin Immunol. 2010 Jun;125(6):1212-7 [20513518.001]
  • [Cites] J Exp Med. 1999 Nov 15;190(10):1465-78 [10562321.001]
  • [Cites] J Immunol. 2000 Jun 15;164(12):6583-92 [10843718.001]
  • [Cites] J Clin Invest. 2002 Jul;110(2):165-75 [12122108.001]
  • [Cites] Pediatr Res. 2002 Sep;52(3):382-6 [12193672.001]
  • [Cites] J Allergy Clin Immunol. 2002 Oct;110(4):607-9 [12373269.001]
  • [Cites] J Exp Med. 2002 Dec 16;196(12):1645-51 [12486107.001]
  • [Cites] Pediatr Allergy Immunol. 2002;13 Suppl 15:38-43 [12688623.001]
  • [Cites] Bioinformatics. 2003 Aug 12;19(12):1461-8 [12912825.001]
  • [Cites] J Appl Physiol (1985). 2004 Mar;96(3):904-10 [14594863.001]
  • [Cites] Pediatr Res. 2004 Apr;55(4):657-65 [14711892.001]
  • [Cites] Am J Respir Cell Mol Biol. 2004 May;30(5):702-9 [14592927.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Aug 1;170(3):306-12 [15130904.001]
  • [Cites] Lab Invest. 1988 Sep;59(3):387-96 [3411939.001]
  • [Cites] Am J Respir Crit Care Med. 1996 Dec;154(6 Pt 1):1834-42 [8970378.001]
  • [Cites] Am J Respir Crit Care Med. 1997 Jan;155(1):130-4 [9001301.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Aug;160(2):705-10 [10430749.001]
  • [Cites] Pediatr Infect Dis J. 2004 Nov;23(11 Suppl):S235-45 [15577579.001]
  • [Cites] Nat Rev Genet. 2005 Apr;6(4):271-86 [15803197.001]
  • [Cites] J Virol. 2005 May;79(9):5363-73 [15827151.001]
  • [Cites] J Virol. 2005 Aug;79(16):10190-9 [16051812.001]
  • [Cites] J Allergy Clin Immunol. 2005 Aug;116(2):267-73 [16083778.001]
  • [Cites] J Infect Dis. 2005 Oct 1;192(7):1149-53 [16136455.001]
  • [Cites] J Allergy Clin Immunol. 2005 Sep;116(3):550-7 [16159623.001]
  • [Cites] J Allergy Clin Immunol. 2005 Sep;116(3):571-7 [16159626.001]
  • [Cites] Immunity. 2005 Oct;23(4):419-29 [16226507.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2007 Jan;292(1):L85-91 [16905639.001]
  • [Cites] J Allergy Clin Immunol. 2007 Feb;119(2):428-33 [17196246.001]
  • [Cites] Eur Respir J. 2007 Apr;29(4):793-803 [17400878.001]
  • [Cites] Clin Exp Immunol. 2007 May;148(2):218-29 [17335559.001]
  • [Cites] J Allergy Clin Immunol. 2007 May;119(5):1105-10 [17353039.001]
  • [Cites] Proc Am Thorac Soc. 2007 Jul;4(3):221-5 [17607003.001]
  • [Cites] J Exp Med. 2007 Oct 29;204(11):2759-69 [17954569.001]
  • [Cites] Nat Med. 2008 Feb;14(2):199-204 [18246079.001]
  • [Cites] Am J Vet Res. 2008 Mar;69(3):416-22 [18312142.001]
  • [Cites] Am J Respir Crit Care Med. 2008 May 15;177(10):1111-21 [18276942.001]
  • [Cites] Nat Med. 2008 Jun;14(6):633-40 [18488036.001]
  • [Cites] Curr Drug Targets. 2008 Jun;9(6):503-10 [18537589.001]
  • [Cites] Clin Microbiol Rev. 2008 Jul;21(3):495-504 [18625684.001]
  • [Cites] Eur Respir J. 2008 Aug;32(2):314-20 [18448489.001]
  • [Cites] J Immunol. 2008 Aug 15;181(4):2925-32 [18684984.001]
  • [Cites] J Infect Dis. 2008 Nov 15;198(10):1435-43 [18828742.001]
  • (PMID = 21029934.001).
  • [ISSN] 1557-8607
  • [Journal-full-title] Immunology and allergy clinics of North America
  • [ISO-abbreviation] Immunol Allergy Clin North Am
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL097134; United States / NIAID NIH HHS / AI / U19 AI070503; United States / NIAID NIH HHS / AI / AI070503; United States / NHLBI NIH HHS / HL / HL097134
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS227372; NLM/ PMC2966841
  •  go-up   go-down


37. Wandroo F, Bell A, Darbyshire P, Pratt G, Stankovic T, Gordon J, Lawson S, Moss P: ZAP-70 is highly expressed in most cases of childhood pre-B cell acute lymphoblastic leukemia. Int J Lab Hematol; 2008 Apr;30(2):149-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZAP-70 is highly expressed in most cases of childhood pre-B cell acute lymphoblastic leukemia.
  • ZAP-70 is, however, expressed in adult B cell chronic lymphocytic leukemia where it correlates with a poor prognosis.
  • We wished to determine if ZAP-70 is also expressed in pediatric B cell malignancy.
  • A quantitative PCR assay for ZAP-70 expression was established and ZAP-70 expression in a range of human B cell lines was compared with expression in the Jurkat T cell line.
  • ZAP-70 expression was then determined in bone marrow lymphoblasts obtained from 12 patients with pre-B cell acute lymphoblastic leukemia (ALL).
  • ZAP-70 expression was not detected in mature B cell lines but was detected in pre-B cell lines at a level comparable to that seen in T cells.
  • ZAP-70 expression was strongly expressed in nine of the 12 cases of primary pre-B cell lymphoblastic leukemia.
  • The T cell-associated protein kinase ZAP-70 is highly expressed in pre-B lineage cells and most cases of pre-B acute lymphoblastic leukemia.
  • ZAP-70 expression may hold prognostic value for pre-B ALL and raises the prospect of a novel therapeutic target.
  • [MeSH-major] B-Lymphocytes / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cells, B-Lymphoid / metabolism. ZAP-70 Protein-Tyrosine Kinase / metabolism
  • [MeSH-minor] Adolescent. Blotting, Western. Bone Marrow Cells / metabolism. Cell Line, Transformed. Cell Line, Tumor. Child. Child, Preschool. Female. Flow Cytometry. Gene Expression. Humans. Jurkat Cells. Male. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18333847.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human
  •  go-up   go-down


38. García-Mata S, Hidalgo-Ovejero A: Anteromedial plantar nodules of the heel in childhood: a variant of the normality? J Pediatr Orthop B; 2010 Jan;19(1):108-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anteromedial plantar nodules of the heel in childhood: a variant of the normality?
  • Sonography showed an accumulation of tissue similar to subcutaneous cell tissue, compatible with fat.
  • MRI was performed in one case, showing an accumulation of fatty tissue similar to subcutaneous cell tissue.

  • MedlinePlus Health Information. consumer health - Foot Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19741551.001).
  • [ISSN] 1473-5865
  • [Journal-full-title] Journal of pediatric orthopedics. Part B
  • [ISO-abbreviation] J Pediatr Orthop B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Semsei AF, Erdélyi DJ, Ungvári I, Kámory E, Csókay B, Andrikovics H, Tordai A, Cságoly E, Falus A, Kovács GT, Szalai C: Association of some rare haplotypes and genotype combinations in the MDR1 gene with childhood acute lymphoblastic leukaemia. Leuk Res; 2008 Aug;32(8):1214-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of some rare haplotypes and genotype combinations in the MDR1 gene with childhood acute lymphoblastic leukaemia.
  • To investigate their possible roles in disease susceptibility and some disease characteristics we genotyped C3435T and G2677T/A polymorphisms in multidrug resistance-1 (MDR1) gene with a single base extension method and the G34A and C421A polymorphisms of the breast cancer resistance protein gene with an allelic discrimination system in 396 children with acute lymphoblastic leukaemia (ALL) and 192 control patients.
  • [MeSH-major] P-Glycoprotein / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Res. 2008 Aug;32(8):1173-5 [18294687.001]
  • (PMID = 18243305.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / P-Glycoprotein
  •  go-up   go-down


40. Baldo M, Bhogal B, Groves RW, Powell J, Wojnarowska F: Childhood vulval lichen sclerosus: autoimmunity to the basement membrane zone protein BP180 and its relationship to autoimmunity. Clin Exp Dermatol; 2010 Jul;35(5):543-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood vulval lichen sclerosus: autoimmunity to the basement membrane zone protein BP180 and its relationship to autoimmunity.
  • In adult women, there are antibody and T-cell responses to proteins in the basement membrane zone (BMZ).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20456392.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Autoantigens; 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / Non-Fibrillar Collagens; 0 / collagen type XVII
  •  go-up   go-down


41. Dai L, Gast A, Horska A, Schrappe M, Bartram CR, Hemminki K, Kumar R, Bermejo JL: A case-control study of childhood acute lymphoblastic leukaemia and polymorphisms in the TGF-beta and receptor genes. Pediatr Blood Cancer; 2009 Jul;52(7):819-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case-control study of childhood acute lymphoblastic leukaemia and polymorphisms in the TGF-beta and receptor genes.
  • BACKGROUND: Inherited genetic variants in critical genes can putatively modulate susceptibility to childhood acute lymphoblastic leukemia (ALL).
  • METHODS: We used allelic discrimination method to genotype 19 polymorphisms in the transforming growth factor-beta1 (TGF-beta1), transforming growth factor-beta receptor 1 (TGF-betaR1) and transforming growth factor-beta receptor 2 (TGF-betaR2) genes in 460 cases of childhood acute ALL and 552 ethnically matched controls.
  • The results, however, did show a marginal association (odds ratio OR 0.76, 95% confidence interval CI 0.59-0.97) of the variant allele for the rs10417924 polymorphism located at 3'untranslated region of the TGF-beta1 gene with the B-cell lineage ALL.
  • No other polymorphism showed any association with childhood ALL susceptibility.
  • A signal of marginal significance for the rs10417924 polymorphism in the TGF-beta1 gene in B-cell lineage ALL showed up with both MDR and imputation techniques.
  • CONCLUSION: These data rule out the role of polymorphisms in the TGF-beta1, TGF-betaR1 and TGF-betaR2 genes in susceptibility to childhood ALL.
  • [MeSH-major] Polymorphism, Single Nucleotide / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Protein-Serine-Threonine Kinases / genetics. Receptors, Transforming Growth Factor beta / genetics. Transforming Growth Factor beta / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19229971.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta; EC 2.7.1.11 / TGF-beta type I receptor; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  •  go-up   go-down


42. Sauvat F, Sarnacki S, Binart N: [Fertility preservation before puberty: from mice to men]. Ann Endocrinol (Paris); 2010 May;71(3):231-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant tumors account for 1% of childhood cancers.
  • Assessment of potential for preservation of fertility should thus be a systematic element of care for children treated for a malignant tumor (high-dose chemotherapy with alkylizing agents, radiation therapy including the gonads) or those receiving hematopoietic stem cell grafts for malignant or benign disease (sickle-cell anemia, immune deficit).

  • MedlinePlus Health Information. consumer health - Puberty.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20362960.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


43. Laane E, Panaretakis T, Pokrovskaja K, Buentke E, Corcoran M, Söderhäll S, Heyman M, Mazur J, Zhivotovsky B, Porwit A, Grandér D: Dexamethasone-induced apoptosis in acute lymphoblastic leukemia involves differential regulation of Bcl-2 family members. Haematologica; 2007 Nov;92(11):1460-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dexamethasone-induced apoptosis in acute lymphoblastic leukemia involves differential regulation of Bcl-2 family members.
  • BACKGROUND AND OBJECTIVES: The mechanism of glucocorticoid -induced apoptosis is not fully understood and early predictive assays based on apoptotic markers for clinical outcome in acute lymphoblastic leukemia (ALL) are scarce.
  • DESIGN AND METHODS: Primary childhood ALL samples, the pre-B ALL cell line RS(4;11), and the T-ALL cell line CCRF-CEM were used.
  • Inhibition of caspase activity did not, however, protect against Dex-induced Bak/Bax activation, loss of Delta psi m or cell death.
  • INTERPRETATION AND CONCLUSIONS: The differential regulation of pro- and anti-apoptotic Bcl-2 family members appears to be a key event in the execution of Dex-induced apoptosis in ALL cell lines, and also indicates a role for these proteins in primary ALL cells.
  • [MeSH-major] Apoptosis / drug effects. Dexamethasone / pharmacology. Gene Expression Regulation, Neoplastic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Proto-Oncogene Proteins c-bcl-2 / genetics
  • [MeSH-minor] Apoptosis Regulatory Proteins / genetics. Caspases / metabolism. Cell Line, Tumor. Flow Cytometry. Humans. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18024393.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 7S5I7G3JQL / Dexamethasone; EC 3.4.22.- / Caspases
  •  go-up   go-down


44. Graubner UB, Porzig S, Jorch N, Kolb R, Wessalowski R, Escherich G, Janka GE: Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer; 2008 Feb;50(2):259-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemia.
  • BACKGROUND: Infections are a major cause of morbidity and mortality in childhood acute lymphoblastic leukemia (ALL) and only limited information is available on infectious complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Infection / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / microbiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17635005.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


45. Mbulaiteye SM, Biggar RJ, Pfeiffer RM, Bakaki PM, Gamache C, Owor AM, Katongole-Mbidde E, Ndugwa CM, Goedert JJ, Whitby D, Engels EA: Water, socioeconomic factors, and human herpesvirus 8 infection in Ugandan children and their mothers. J Acquir Immune Defic Syndr; 2005 Apr 1;38(4):474-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transmission occurs during childhood within families by unclear routes.
  • METHODS: We evaluated 600 Ugandan children with sickle cell disease and their mothers for factors associated with HHV-8 seropositivity in a cross-sectional study.
  • [MeSH-minor] Adolescent. Adult. Anemia, Sickle Cell / complications. Anemia, Sickle Cell / epidemiology. Child. Child, Preschool. Educational Status. Fathers. Female. Herpesvirus 8, Human. Humans. Income. Infant. Odds Ratio. Siblings. Uganda / epidemiology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15764964.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CO / N01-CO-12400; United States / NCI NIH HHS / CP / N02-CP-91027
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


46. Stanulla M, Schaeffeler E, Möricke A, Coulthard SA, Cario G, Schrauder A, Kaatsch P, Dördelmann M, Welte K, Zimmermann M, Reiter A, Eichelbaum M, Riehm H, Schrappe M, Schwab M: Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols. Blood; 2009 Aug 13;114(7):1314-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols.
  • Treatment for childhood acute lymphoblastic leukemia (ALL) regularly includes the use of thiopurine drugs.
  • Importantly, childhood ALL patients with low TPMT activity have been considered to be at increased risk of developing therapy-associated acute myeloid leukemia and brain tumors.
  • Thus, TPMT does not play a major role in the etiology of secondary malignant neoplasm after treatment for childhood ALL, according to Berlin-Frankfurt-Münster strategies.
  • [MeSH-major] Brain Neoplasms / genetics. Leukemia, Myeloid, Acute / enzymology. Methyltransferases / genetics. Neoplasms, Second Primary / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


47. Pole JD, Mustard CA, To T, Beyene J, Allen AC: Antenatal steroid therapy for fetal lung maturation and the subsequent risk of childhood asthma: a longitudinal analysis. J Pregnancy; 2010;2010:789748
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antenatal steroid therapy for fetal lung maturation and the subsequent risk of childhood asthma: a longitudinal analysis.
  • This study was designed to test the hypothesis that fetal exposure to corticosteroids in the antenatal period is an independent risk factor for the development of asthma in early childhood with little or no effect in later childhood.
  • Exposure to corticosteroids during pregnancy was associated with a risk of asthma in childhood between 3-5 years of age: adjusted hazard ratio of 1.19 (95% confidence interval: 1.03, 1.39), with no association noted after 5 years of age: adjusted hazard ratio for 5-7 years was 1.06 (95% confidence interval: 0.86, 1.30) and for 8 or greater years was 0.74 (95% confidence interval: 0.54, 1.03).

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma in Children.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1996 Oct 19;348(9034):1060-4 [8874457.001]
  • [Cites] Pediatr Pulmonol. 2003 Aug;36(2):131-6 [12833492.001]
  • [Cites] Arch Dis Child. 2001 Jan;84(1):40-44 [11124782.001]
  • [Cites] Ann Med. 2000 Sep;32(6):390-6 [11028686.001]
  • [Cites] Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):408-10 [10224460.001]
  • [Cites] Semin Neonatol. 2001 Aug;6(4):309-17 [11972432.001]
  • [Cites] Am J Epidemiol. 1999 Sep 1;150(5):528-31 [10472953.001]
  • [Cites] Trends Endocrinol Metab. 2002 Nov;13(9):373-80 [12367818.001]
  • [Cites] Hypertension. 2002 Nov;40(5):729-34 [12411469.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Mar;161(3 Pt 2):S202-6 [10712375.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Jul;160(1):227-36 [10390405.001]
  • [Cites] Am J Respir Crit Care Med. 1994 Sep;150(3):759-65 [8087349.001]
  • [Cites] FASEB J. 2002 Jul;16(9):1017-26 [12087063.001]
  • [Cites] Eur J Epidemiol. 1996 Dec;12(6):583-8 [8982617.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1617-22 [10556130.001]
  • [Cites] Allergy. 2000 Jan;55(1):2-10 [10696851.001]
  • [Cites] Eur Respir J. 1998 Aug;12(2):315-35 [9727780.001]
  • [Cites] Pediatrics. 2000 Jul;106(1):E2 [10878171.001]
  • [Cites] Trends Endocrinol Metab. 2002 Nov;13(9):403-8 [12367823.001]
  • [Cites] Pediatr Pulmonol. 1988;5(1):27-30 [3174273.001]
  • [Cites] Health Rep. 1999 Spring;10(4):57-67(ENG); 59-71(FRE) [10607413.001]
  • [Cites] Bioessays. 2003 Mar;25(3):212-20 [12596225.001]
  • [Cites] Thorax. 1999 Oct;54(10):938-46 [10491459.001]
  • [Cites] Curr Opin Pulm Med. 1999 Jan;5(1):4-9 [10813243.001]
  • [Cites] Chest. 2001 Mar;119(3):708-13 [11243946.001]
  • [Cites] J Asthma. 2000;37(7):589-94 [11059526.001]
  • [Cites] Am J Respir Crit Care Med. 1996 Sep;154(3 Pt 1):681-8 [8810605.001]
  • [Cites] Pediatrics. 2001 Sep;108(3):741-8 [11533345.001]
  • [Cites] Can Respir J. 1999 Jan-Feb;6(1):97-101 [10202223.001]
  • [Cites] Med Hypotheses. 2008;70(5):981-9 [17961931.001]
  • [Cites] Adv Exp Med Biol. 1996;409:55-60 [9095223.001]
  • [Cites] Am J Epidemiol. 2001 Apr 1;153(7):653-8 [11282792.001]
  • [Cites] Ciba Found Symp. 1997;206:220-8; discussion 228-32 [9257015.001]
  • [Cites] J Allergy Clin Immunol. 2001 Apr;107(4):732-3 [11295666.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2001 Nov;28(11):952-6 [11703404.001]
  • [Cites] Clin Perinatol. 1998 Dec;25(4):983-97 [9891625.001]
  • [Cites] Can Respir J. 2004 Mar;11(2):141-5 [15045045.001]
  • [Cites] J Theor Biol. 2001 Jun 7;210(3):345-6 [11397135.001]
  • [Cites] J Pediatr. 2000 Jul;137(1):1-3 [10891810.001]
  • [Cites] J Asthma. 2009 Feb;46(1):47-52 [19191137.001]
  • [Cites] Environ Health Perspect. 2002 Apr;110 Suppl 2:211-6 [11929730.001]
  • [Cites] Pediatrics. 2002 Feb;109(2):330-8 [11826218.001]
  • [Cites] Annu Rev Physiol. 2000;62:825-46 [10845113.001]
  • [Cites] Obstet Gynecol. 1998 Sep;92(3):435-40 [9721785.001]
  • [Cites] Clin Exp Pharmacol Physiol. 1999 Jul;26(7):550-2 [10405786.001]
  • [Cites] Eur Respir J. 1995 Mar;8(3):349-56 [7789476.001]
  • [Cites] Ann Epidemiol. 2001 Jan;11(1):7-12 [11164114.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Feb;159(2):403-10 [9927350.001]
  • [Cites] Pediatr Res. 2000 Mar;47(3):291-300 [10709726.001]
  • [Cites] J Allergy Clin Immunol. 2003 Mar;111(3 Suppl):S785-92 [12618744.001]
  • [Cites] Can Respir J. 2002 Nov-Dec;9(6):407-12 [12522486.001]
  • [Cites] Clin Rev Allergy Immunol. 2002 Feb;22(1):33-44 [11803801.001]
  • [Cites] J Obstet Gynaecol Can. 2003 Jan;25(1):45-52 [12548324.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2003 Apr;284(4):L633-42 [12471018.001]
  • [Cites] N Engl J Med. 2000 Aug 24;343(8):538-43 [10954761.001]
  • [Cites] Trends Endocrinol Metab. 1999 Apr;10(3):86-91 [10322400.001]
  • [Cites] Am J Epidemiol. 1996 Mar 15;143(6):570-7 [8610674.001]
  • [Cites] Semin Neonatol. 2001 Aug;6(4):331-42 [11972434.001]
  • [Cites] Pediatrics. 1990 Jul;86(1):65-70 [2193304.001]
  • [Cites] Eur Respir J Suppl. 1998 Jul;27:46s-51s [9699784.001]
  • [Cites] Pediatrics. 2000 Nov;106(5):1070-9 [11061777.001]
  • [Cites] Brain Res. 1999 Nov 6;846(2):253-9 [10556643.001]
  • [Cites] Endocr Rev. 2000 Oct;21(5):514-50 [11041447.001]
  • [Cites] Curr Opin Allergy Clin Immunol. 2009 Oct;9(5):417-26 [19652594.001]
  • [RetractionIn] J Pregnancy. 2016;2016:6212584 [27818799.001]
  • (PMID = 21490744.001).
  • [ISSN] 2090-2735
  • [Journal-full-title] Journal of pregnancy
  • [ISO-abbreviation] J Pregnancy
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / / MOP-77693
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Pulmonary Surfactants
  • [Other-IDs] NLM/ PMC3065803
  • [General-notes] NLM/ Original DateCompleted: 20110714
  •  go-up   go-down


48. Maniar TN, Braunstein I, Keefe S, Hussen S, Abrams T, De Michele A, El-Deiry WS: Childhood ALL and second neoplasms. Cancer Biol Ther; 2007 Oct;6(10):1525-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood ALL and second neoplasms.
  • Second malignancies are a significant concern for survivors of childhood acute lymphoblastic leukemia (ALL), in particular patients who have been treated with cranial irradiation.
  • Breast cancer can occur in association with meningioma, but is not thought to be a consequence of treatment for childhood ALL.
  • We describe the molecular genetics and therapy of childhood ALL, the molecular genetics of meningioma, as well as the possible association between meningioma and breast cancer.
  • [MeSH-major] Breast Neoplasms / epidemiology. Meningeal Neoplasms / epidemiology. Meningioma / epidemiology. Neoplasms, Second Primary / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17952026.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 96
  •  go-up   go-down


49. Miranda P, Simal JA, Vila M, Hernández M, Menor F, Alvarez-Garijo JA: Posterior fossa clear cell meningioma without dural attachment in a child. Childs Nerv Syst; 2009 Mar;25(3):389-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posterior fossa clear cell meningioma without dural attachment in a child.
  • INTRODUCTION: Meningiomas are relatively uncommon in childhood.
  • They represent 1% to 2% of all intracranial tumours of infancy and childhood and 1.5% to 1.8% of all intracranial meningiomas.
  • Clear cell meningioma is a histological distinctive uncommon variant of meningioma that may behave aggressively with local recurrence and progression as well as cerebrospinal fluid-borne metastasis.
  • CASE REPORT: In this study, the authors present a rare case of posterior fossa clear cell meningioma without dural attachment in a child with severe brainstem and cervical spinal cord displacement and discuss the clinical and radiological features as well as treatment considerations.

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurocirugia (Astur). 2004 Dec;15(6):525-42 [15632989.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(2):111-8 [10189491.001]
  • [Cites] Brain Pathol. 2003 Jul;13(3):386-408 [12946028.001]
  • [Cites] Pediatr Neurosurg. 1992;18(1):16-23 [1419837.001]
  • [Cites] Crit Rev Neurosurg. 1999 May 25;9(3):180-188 [10369973.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Neurol Med Chir (Tokyo). 2007 Aug;47(8):364-6 [17721053.001]
  • [Cites] Childs Nerv Syst. 2000 Jul;16(7):406-16 [10958549.001]
  • [Cites] J Neurosurg. 2002 Nov;97(5):1078-82 [12450029.001]
  • [Cites] Neurosurg Rev. 2008 Jan;31(1):19-32; discussion 32-3 [17882459.001]
  • [Cites] Childs Nerv Syst. 1996 Oct;12(10):582-8; discussion 589 [8934017.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Mar-Apr;24(3):199-204 [11990306.001]
  • (PMID = 19030867.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


50. Leclerc GJ, Mou C, Leclerc GM, Mian AM, Barredo JC: Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy. Leukemia; 2010 Mar;24(3):552-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy.
  • Children with acute lymphoblastic leukemia (ALL) diagnosed with resistant phenotypes, and those who relapse, have a dismal prognosis for cure.
  • We demonstrated that histone deacetylase-1 (HDAC1) is recruited by NFY and Sp1 transcription factors to the FPGS promoter in ALL cell lines.
  • Combination treatment with MTX plus SAHA significantly increased cytotoxicity and apoptosis in B- and T-ALL cell lines as compared with each drug alone (CI<or=0.8).
  • Therefore, HDACI-induced FPGS expression increases the accumulation of MTX-PG(3-7) and cytotoxicity in ALL cell lines, which is potentiated by DHFR and TS downregulation.
  • [MeSH-major] Histone Deacetylase Inhibitors / pharmacology. Methotrexate / analogs & derivatives. Peptide Synthases / genetics. Polyglutamic Acid / analogs & derivatives. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CCAAT-Binding Factor / physiology. Cell Line, Tumor. Exons. Gene Expression Regulation, Enzymologic / drug effects. Histone Deacetylase 1 / physiology. Humans. Hydroxamic Acids / administration & dosage. Sp1 Transcription Factor / physiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Vorinostat .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leukemia. 2011 Feb;25(2):359-61 [21072050.001]
  • (PMID = 20072153.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098152
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CCAAT-Binding Factor; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / NFYB protein, human; 0 / Sp1 Transcription Factor; 25513-46-6 / Polyglutamic Acid; 58IFB293JI / vorinostat; 82334-40-5 / methotrexate polyglutamate; EC 3.5.1.98 / HDAC1 protein, human; EC 3.5.1.98 / Histone Deacetylase 1; EC 6.3.2.- / Peptide Synthases; EC 6.3.2.17 / folylpolyglutamate synthetase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


51. Lönnerholm G, Thörn I, Sundström C, Frost BM, Abrahamsson J, Behrendtz M, Heldrup J, Jacobsson S, Li A, Olofsson T, Porwit A, Söderhäll S, Larsson R, Forestier E: In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia. Leuk Res; 2009 Jan;33(1):46-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia.
  • Leukemic cells from 85 children with newly diagnosed precursor B-lineage ALL were tested for in vitro drug sensitivity to a panel of anti-cancer drugs.
  • Thus, data show that in vitro drug sensitivity at diagnosis is correlated to cell kill during induction therapy as measured by MRD day 29.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm, Residual. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


52. Gorman MF, Ji L, Ko RH, Barnette P, Bostrom B, Hutchinson R, Raetz E, Seibel NL, Twist CJ, Eckroth E, Sposto R, Gaynon PS, Loh ML: Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study. Pediatr Blood Cancer; 2010 Sep;55(3):421-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study.
  • BACKGROUND: Current event-free survival (EFS) rates for children with newly diagnosed acute myeloid leukemia (AML) approach 50-60%.
  • We hypothesize that further improvements in survival are unlikely to be achieved with traditional approaches such as dose intensive chemotherapy or hematopoietic stem cell transplants, since these therapies have been rigorously explored in clinical trials.
  • PROCEDURE: We performed a retrospective cohort review of pediatric patients with relapsed and refractory AML (rAML) previously treated at TACL institutions between the years of 1995 and 2004.
  • [MeSH-major] Leukemia, Myeloid, Acute / drug therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20658611.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K22 CA113557
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


53. Santoro A, Cannella S, Trizzino A, Lo Nigro L, Corsello G, Aricò M: A single amino acid change A91V in perforin: a novel, frequent predisposing factor to childhood acute lymphoblastic leukemia? Haematologica; 2005 May;90(5):697-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single amino acid change A91V in perforin: a novel, frequent predisposing factor to childhood acute lymphoblastic leukemia?
  • We screened 100 children with acute lymphoblastic leukemia (ALL) to assess the incidence of single amino acid change A91V in perforin.
  • A91V is a novel and frequent predisposing factor for childhood ALL.
  • [MeSH-major] Amino Acid Substitution. Membrane Glycoproteins / genetics. Mutation, Missense. Pore Forming Cytotoxic Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15921391.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Membrane Glycoproteins; 0 / Pore Forming Cytotoxic Proteins; 126465-35-8 / Perforin
  •  go-up   go-down


54. Sellin CI, Davoust N, Guillaume V, Baas D, Belin MF, Buckland R, Wild TF, Horvat B: High pathogenicity of wild-type measles virus infection in CD150 (SLAM) transgenic mice. J Virol; 2006 Jul;80(13):6420-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Measles virus (MV) infection causes an acute childhood disease, associated in certain cases with infection of the central nervous system and development of a severe neurological disease.
  • We have generated transgenic mice ubiquitously expressing the human protein SLAM (signaling lymphocytic activation molecule), or CD150, recently identified as an MV receptor.
  • Intranasal infection of SLAM transgenic suckling mice leads to MV spread to different organs and the development of an acute neurological syndrome, characterized by lethargy, seizures, ataxia, weight loss, and death within 3 weeks.
  • [MeSH-minor] Animals. Antibodies, Viral / blood. Antigens, CD. Humans. Mice. Mice, Transgenic. Receptors, Cell Surface. Recombinant Proteins / genetics. Recombinant Proteins / therapeutic use

  • Genetic Alliance. consumer health - Measles.
  • MedlinePlus Health Information. consumer health - Measles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1999 Sep 3;98(5):629-40 [10490102.001]
  • [Cites] J Virol. 1999 Aug;73(8):6916-22 [10400789.001]
  • [Cites] J Infect Dis. 2005 Jan 15;191(2):207-14 [15609230.001]
  • [Cites] Immunity. 2005 Feb;22(2):247-57 [15723812.001]
  • [Cites] J Immunol. 2005 Sep 1;175(5):3252-61 [16116216.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Sep;49(9):3755-61 [16127050.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16415-20 [16260741.001]
  • [Cites] J Virol. 2000 Feb;74(3):1373-82 [10627548.001]
  • [Cites] J Virol. 2000 May;74(10):4672-8 [10775604.001]
  • [Cites] Nature. 2000 Aug 24;406(6798):893-7 [10972291.001]
  • [Cites] J Biol Chem. 2000 Sep 8;275(36):28100-9 [10831600.001]
  • [Cites] J Virol. 2001 Feb;75(4):1594-600 [11160657.001]
  • [Cites] Trends Microbiol. 2001 Jan;9(1):19-23 [11166238.001]
  • [Cites] Immunity. 2001 Jan;14(1):69-79 [11163231.001]
  • [Cites] J Virol. 2001 Jul;75(13):5842-50 [11390585.001]
  • [Cites] J Virol. 2002 Feb;76(3):1505-9 [11773423.001]
  • [Cites] J Gen Virol. 2002 Jun;83(Pt 6):1437-43 [12029159.001]
  • [Cites] J Med Virol. 2002 Nov;68(3):433-40 [12226833.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Nat Immunol. 2003 Jan;4(1):19-24 [12496974.001]
  • [Cites] J Virol. 2003 Mar;77(6):3505-15 [12610126.001]
  • [Cites] J Infect Dis. 2003 May 15;187 Suppl 1:S8-14 [12721886.001]
  • [Cites] Science. 2003 Aug 8;301(5634):804 [12907792.001]
  • [Cites] J Gen Virol. 2003 Sep;84(Pt 9):2381-8 [12917459.001]
  • [Cites] J Virol. 2004 Jan;78(1):146-57 [14671096.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5628-33 [15056763.001]
  • [Cites] Virology. 2004 Jun 1;323(2):292-302 [15193925.001]
  • [Cites] Expert Opin Biol Ther. 2004 Oct;4(10):1685-92 [15461580.001]
  • [Cites] Pediatrics. 1977 Feb;59(2):232-9 [264657.001]
  • [Cites] J Infect Dis. 1987 Sep;156(3):436-41 [3611830.001]
  • [Cites] Virus Res. 1988 May;10(2-3):137-52 [2457995.001]
  • [Cites] Nucleic Acids Res. 1989 Oct 25;17(20):8389 [2813075.001]
  • [Cites] Arch Fr Pediatr. 1990 Apr;47(4):275-7 [2363615.001]
  • [Cites] Curr Top Microbiol Immunol. 1992;176:63-74 [1600755.001]
  • [Cites] Clin Infect Dis. 1993 May;16(5):654-60 [8323578.001]
  • [Cites] Curr Top Microbiol Immunol. 1995;191:1-12 [7789153.001]
  • [Cites] Curr Top Microbiol Immunol. 1995;191:149-66 [7789158.001]
  • [Cites] Immunology. 1995 Apr;84(4):619-25 [7790036.001]
  • [Cites] Nature. 1995 Jul 20;376(6537):260-3 [7617038.001]
  • [Cites] Neurology. 1996 Feb;46(2):586-7 [8614546.001]
  • [Cites] J Neuropathol Exp Neurol. 1996 Apr;55(4):471-80 [8786407.001]
  • [Cites] J Gen Virol. 1996 Jul;77 ( Pt 7):1477-81 [8757989.001]
  • [Cites] J Virol. 1996 Oct;70(10):6673-81 [8794303.001]
  • [Cites] J Exp Med. 1997 Mar 17;185(6):993-1004 [9091591.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4659-63 [9114047.001]
  • [Cites] Lancet. 1997 May 3;349(9061):1269-76 [9142060.001]
  • [Cites] J Virol. 1997 Oct;71(10):7214-9 [9311794.001]
  • [Cites] Brain Res Bull. 1997;44(3):213-20 [9323433.001]
  • [Cites] Acta Cytol. 1998 May-Jun;42(3):729-33 [9622696.001]
  • [Cites] Ann Intern Med. 1998 Jul 15;129(2):104-6 [9669968.001]
  • [Cites] J Virol. 1998 Sep;72(9):7420-7 [9696838.001]
  • [Cites] J Comp Pathol. 1998 Oct;119(3):201-25 [9807724.001]
  • [Cites] Acta Neuropathol. 1998 Dec;96(6):637-42 [9845294.001]
  • [Cites] Neurology. 1999 Mar 23;52(5):1074-7 [10102434.001]
  • [Cites] Vet Microbiol. 1999 Sep 1;69(1-2):3-13 [10515262.001]
  • (PMID = 16775330.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Immunoglobulins; 0 / Receptors, Cell Surface; 0 / Recombinant Proteins; 169535-43-7 / CD150 antigen
  • [Other-IDs] NLM/ PMC1488937
  •  go-up   go-down


55. Amégbor K, Darre T, Alfa AK, Napo-Koura G: [Epidemiology and pathological profile of childhood ovary tumours in Togo: about 32 cases]. Bull Cancer; 2009 Jun;96(6):709-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiology and pathological profile of childhood ovary tumours in Togo: about 32 cases].
  • PURPOSE: Tumours of the ovary is rare in childhood.
  • MATERIAL AND METHODS: Retrospective review of the epidemiologic and pathologic features of the ovary tumours in childhood (0 to 15 years), observed from 1988 to 2007 at the laboratory of pathology of the Tokoin teaching hospital in Lomé, Togo.
  • RESULTS: During our study period, we observed 32 cases of childhood ovary tumours that represent 8.16% of all ovarian tumours.
  • Histologically it was germ cell tumours in 40.6% of cases (mature teratomas: 34.4% ; immature teratomas: 3.1% ; yolk sac tumours: 3.1%), sex cord-stromal tumours in 21.8% of cases (granulosa cell tumours: 18.7% ; fibroma: 3.1%) and Burkitt lymphoma in 37.6%.
  • CONCLUSION: The childhood ovary tumours although rare, exist in Togo dominated by Burkitt lymphoma.
  • [MeSH-minor] Adolescent. Biopsy. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / pathology. Child. Child, Preschool. Female. Humans. Infant. Neoplasms, Germ Cell and Embryonal / epidemiology. Neoplasms, Germ Cell and Embryonal / pathology. Ovary / pathology. Retrospective Studies. Sex Cord-Gonadal Stromal Tumors / epidemiology. Sex Cord-Gonadal Stromal Tumors / pathology. Teratoma / epidemiology. Teratoma / pathology. Togo / epidemiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19457758.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


56. Tanabe F, Kasai H, Morimoto M, Oh S, Takada H, Hara T, Ito M: Novel Heterogenous CHS1 Mutations Identified in Five Japanese Patients with Chediak-Higashi Syndrome. Case Rep Med; 2010;2010:464671
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient suffered from infections in childhood and had visual disturbance and albinism of the skin and hair.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2002 Sep 16;21(18):4785-95 [12234919.001]
  • [Cites] Curr Mol Med. 2002 Aug;2(5):469-77 [12125812.001]
  • [Cites] Int Immunopharmacol. 2007 Jul;7(7):973-80 [17499200.001]
  • [Cites] J Invest Dermatol. 2007 Nov;127(11):2674-7 [17554367.001]
  • [Cites] Hum Mol Genet. 1997 Jul;6(7):1091-8 [9215680.001]
  • [Cites] J Biol Chem. 1997 Nov 21;272(47):29790-4 [9368050.001]
  • [Cites] J Cell Biol. 1998 Jun 1;141(5):1121-34 [9606205.001]
  • [Cites] J Leukoc Biol. 1990 Nov;48(5):377-81 [2230592.001]
  • [Cites] Int Immunopharmacol. 2009 Mar;9(3):366-70 [19185618.001]
  • [Cites] J Leukoc Biol. 2000 May;67(5):749-55 [10811017.001]
  • [Cites] Clin Exp Immunol. 2001 Aug;125(2):283-90 [11529921.001]
  • [Cites] Am J Med Genet. 2002 Feb 15;108(1):16-22 [11857544.001]
  • [Cites] Pigment Cell Res. 2002 Aug;15(4):251-7 [12100490.001]
  • [Cites] Traffic. 2003 Jun;4(6):403-15 [12753649.001]
  • [Cites] Curr Opin Hematol. 2008 Jan;15(1):22-9 [18043242.001]
  • [Cites] Nature. 1996 Jul 18;382(6588):262-5 [8717042.001]
  • [Cites] Nat Genet. 1996 Nov;14(3):307-11 [8896560.001]
  • [Cites] Biochem Biophys Res Commun. 1989 Apr 28;160(2):433-40 [2541700.001]
  • [Cites] Mol Genet Metab. 2005 Jun;85(2):125-32 [15896657.001]
  • (PMID = 21209802.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3014749
  •  go-up   go-down


57. Tamai H, Yamaguchi H, Hamaguchi H, Yagasaki F, Bessho M, Kobayashi T, Akiyama H, Sakamaki H, Takahashi S, Tojo A, Ohmine K, Ozawa K, Okumura H, Nakao S, Arai A, Miura O, Toyota S, Gomi S, Murai Y, Usui N, Miyazawa K, Ohyashiki K, Takahashi N, Sawada K, Kato A, Oshimi K, Inokuchi K, Dan K: Clinical features of adult acute leukemia with 11q23 abnormalities in Japan: a co-operative multicenter study. Int J Hematol; 2008 Mar;87(2):195-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features of adult acute leukemia with 11q23 abnormalities in Japan: a co-operative multicenter study.
  • To clarify the clinical features of adult patients with acute leukemia (AL) with 11q23 abnormalities, we performed a retrospective analysis of data from 58 adult Japanese patients: 51 with acute myeloid leukemia (AML), and 7 with acute lymphoblastic leukemia (ALL).
  • The incidence of patients with t(11;19) was higher than those in the US and Europe, and the incidence of t(4;11) was lower than that in childhood.
  • AML patients with 11q23 aged <60 years in the first CR who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) showed a more favorable outcome than those treated without allo-HSCT, although the differences were not statistically significant (P = 0.322 for DFS, P = 0.138 for OS).
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Adult. Cohort Studies. Disease-Free Survival. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Retrospective Studies. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Oct 1;100(7):2292-302 [12239137.001]
  • [Cites] Blood. 1997 Dec 1;90(11):4532-8 [9373264.001]
  • [Cites] Leukemia. 1994 Nov;8(11):1918-22 [7967737.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6236-9 [8016145.001]
  • [Cites] Leukemia. 1998 May;12(5):801-4 [9593284.001]
  • [Cites] Leukemia. 1995 Aug;9(8):1299-304 [7643616.001]
  • [Cites] Leukemia. 1999 Jul;13(7):1013-7 [10400416.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10735-9 [1720549.001]
  • [Cites] Am J Clin Pathol. 2004 Aug;122(2):298-306 [15323147.001]
  • [Cites] Cancer Res. 1998 Jan 1;58(1):55-9 [9426057.001]
  • [Cites] Leuk Res. 1999 Jun;23(6):585-8 [10374852.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3254-61 [12149299.001]
  • [Cites] Leuk Res. 2000 Jun;24(6):481-6 [10781681.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12110-4 [7991593.001]
  • [Cites] Leukemia. 1998 May;12(5):805-10 [9593285.001]
  • [Cites] Hum Pathol. 1987 Mar;18(3):211-25 [3546071.001]
  • [Cites] Blood. 1994 Sep 15;84(6):1747-52 [8080983.001]
  • [Cites] Leukemia. 1995 May;9(5):762-9 [7769837.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] N Engl J Med. 1993 Sep 23;329(13):909-14 [8361504.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2395-402 [12805060.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2327-30 [8162575.001]
  • [Cites] Leukemia. 1998 May;12(5):788-91 [9593282.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:118-45 [15561680.001]
  • [Cites] Blood. 1993 Dec 15;82(12):3705-11 [8260707.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5695-707 [11607819.001]
  • [Cites] Haematologica. 1998 Apr;83(4):350-7 [9592986.001]
  • [Cites] Br J Haematol. 2001 Sep;114(3):539-43 [11552977.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5624-8 [8242616.001]
  • [Cites] Cancer. 2004 Sep 15;101(6):1420-7 [15368330.001]
  • [Cites] Oncogene. 1993 Nov;8(11):3085-92 [8414510.001]
  • [Cites] Leukemia. 1998 May;12(5):792-800 [9593283.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] Leukemia. 1998 Jan;12(1):25-33 [9436917.001]
  • [Cites] Blood. 1995 Sep 15;86(6):2073-6 [7662954.001]
  • [Cites] Br J Haematol. 1999 Sep;106(3):614-26 [10468849.001]
  • [Cites] J Clin Invest. 1994 Jan;93(1):429-37 [8282816.001]
  • (PMID = 18253706.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  •  go-up   go-down


58. West DW, Burd NA, Staples AW, Phillips SM: Human exercise-mediated skeletal muscle hypertrophy is an intrinsic process. Int J Biochem Cell Biol; 2010 Sep;42(9):1371-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, while these hormones are clearly anabolic during childhood and puberty, or when given at supraphysiological exogenous doses, the transient post-exercise elevations in hormone concentration are of little consequence to the either the acute protein synthetic response or to a hypertrophic phenotype after resistance training.
  • Thus, the acute post-exercise increases in systemic hormones are in no way a proxy marker for anabolism since they do not underpin the capacity of the muscle to hypertrophy in any measurable way.
  • In contrast, the acute activation of intrinsically located signalling proteins such as p70(S6K) and the acute elevation of muscle protein synthesis are more reflective of the potential to increase in muscle mass with resistance training.

  • Genetic Alliance. consumer health - Muscle hypertrophy.
  • MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20541030.001).
  • [ISSN] 1878-5875
  • [Journal-full-title] The international journal of biochemistry & cell biology
  • [ISO-abbreviation] Int. J. Biochem. Cell Biol.
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 3XMK78S47O / Testosterone
  •  go-up   go-down


59. Boily G, Beaulieu P, Healy J, Sinnett D: Connections between ETV6-modulated genes: identification of shared features. Cancer Inform; 2008;6:183-201
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Accumulating genetic and functional evidence point to ETV6 as being the tumour suppressor gene targeted by the deletions at chromosome 12p12-13 found in various cancers, particularly childhood leukemia.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2004 Jan;36(1):40-5 [14702039.001]
  • [Cites] Cell Death Differ. 2004 Apr;11(4):381-9 [14685163.001]
  • [Cites] Blood Cells Mol Dis. 2003 Nov-Dec;31(3):342-50 [14636650.001]
  • [Cites] Gene. 2003 Aug 14;313:43-57 [12957376.001]
  • [Cites] Development. 2003 Oct;130(20):4907-17 [12930781.001]
  • [Cites] Eur J Hum Genet. 2002 Jan;10(1):62-71 [11896457.001]
  • [Cites] In Silico Biol. 2002;2(1):S17-26 [11808874.001]
  • [Cites] Nat Genet. 2001 Oct;29(2):153-9 [11547334.001]
  • [Cites] Oncogene. 2000 Dec 18;19(55):6533-48 [11175369.001]
  • [Cites] Nat Genet. 2000 May;25(1):25-9 [10802651.001]
  • [Cites] Genes Cells. 1999 Dec;4(12):685-96 [10620014.001]
  • [Cites] Br J Haematol. 2007 Jan;136(1):48-62 [17069581.001]
  • [Cites] Oncogene. 2005 May 26;24(23):3737-47 [15735714.001]
  • [Cites] BMC Genomics. 2005;6:37 [15762987.001]
  • [Cites] Nucleic Acids Res. 1998 Mar 1;26(5):1135-43 [9469818.001]
  • [Cites] Mol Cell Biol. 1998 Nov;18(11):6305-15 [9774647.001]
  • [Cites] Bioinformatics. 1998;14(3):290-4 [9614273.001]
  • [Cites] Oncogene. 1997 Dec 11;15(24):2929-37 [9416836.001]
  • [Cites] Leukemia. 1997 Sep;11(9):1459-64 [9305598.001]
  • [Cites] Mol Cell Biol. 1996 Apr;16(4):1479-89 [8657121.001]
  • [Cites] Blood. 1996 Aug 1;88(3):785-94 [8704231.001]
  • [Cites] EMBO J. 1994 Aug 1;13(15):3505-16 [8062827.001]
  • [Cites] Mol Cell Biol. 1993 Mar;13(3):1854-62 [8441418.001]
  • [Cites] Curr Opin Genet Dev. 2004 Oct;14(5):527-32 [15380244.001]
  • [Cites] Leukemia. 2004 Sep;18(9):1499-504 [15284860.001]
  • [Cites] J Biol. 2003;2(2):11 [12814519.001]
  • [Cites] J Biol. 2003;2(2):13 [12760745.001]
  • [Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W249-52 [15215389.001]
  • [Cites] In Silico Biol. 2004;4(1):55-61 [15089753.001]
  • [Cites] Nat Rev Genet. 2004 Apr;5(4):276-87 [15131651.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D493-6 [14681465.001]
  • (PMID = 19259410.001).
  • [ISSN] 1176-9351
  • [Journal-full-title] Cancer informatics
  • [ISO-abbreviation] Cancer Inform
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2623305
  • [Keywords] NOTNLM ; ETV6 / ets member / leukemogenesis / microarrays / transcription factor
  •  go-up   go-down


60. Ladas EJ, Kroll DJ, Oberlies NH, Cheng B, Ndao DH, Rheingold SR, Kelly KM: A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL). Cancer; 2010 Jan 15;116(2):506-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL).
  • METHODS: In a double-blind study, children with acute lymphoblastic leukemia (ALL) and hepatic toxicity were randomized to MT or placebo orally for 28 days.
  • To assess MT in vitro, the authors evaluated supratherapeutic concentrations in an ALL cell line.
  • Future study is needed to determine the most effective dose and duration of MT and its effect on hepatotoxicity and leukemia-free survival.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Org Biomol Chem. 2003 May 21;1(10):1684-9 [12926355.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2548-55 [18039957.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Apr;26(4):217-26 [15087948.001]
  • [Cites] Eur J Drug Metab Pharmacokinet. 1990 Oct-Dec;15(4):333-8 [2088770.001]
  • [Cites] Pediatr Hematol Oncol. 1991 Oct-Dec;8(4):301-12 [1782110.001]
  • [Cites] Haematologica. 1993 Sep-Oct;78(5):340-1 [8314167.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1560-6 [9193353.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4448-57 [15899838.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2944-50 [16675592.001]
  • [Cites] Science. 2006 Jul 21;313(5785):303-4 [16857924.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1165-73 [16609069.001]
  • [Cites] Invest New Drugs. 2007 Apr;25(2):139-46 [17077998.001]
  • [Cites] Integr Cancer Ther. 2007 Jun;6(2):120-9 [17548791.001]
  • [Cites] Integr Cancer Ther. 2007 Jun;6(2):146-57 [17548793.001]
  • [Cites] Integr Cancer Ther. 2007 Jun;6(2):158-65 [17548794.001]
  • [Cites] Integr Cancer Ther. 2007 Jun;6(2):166-73 [17548795.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(4):CD003620 [17943794.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5800-7 [18089878.001]
  • [Cites] Case Manager. 2004 Mar-Apr;15(2):28-32 [15026765.001]
  • (PMID = 20014183.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA104286-05; United States / NCI NIH HHS / CA / R01 CA104286; United States / NCI NIH HHS / CA / R01 CA104286-05
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Placebos
  • [Other-IDs] NLM/ NIHMS150158; NLM/ PMC3542639
  •  go-up   go-down


61. Tung WL, Quek C: GenSo-FDSS: a neural-fuzzy decision support system for pediatric ALL cancer subtype identification using gene expression data. Artif Intell Med; 2005 Jan;33(1):61-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GenSo-FDSS: a neural-fuzzy decision support system for pediatric ALL cancer subtype identification using gene expression data.
  • OBJECTIVE: Acute lymphoblastic leukemia (ALL) is the most common malignancy of childhood, representing nearly one third of all pediatric cancers.
  • Currently, the treatment of pediatric ALL is centered on tailoring the intensity of the therapy applied to a patient's risk of relapse, which is linked to the type of leukemia the patient has.
  • Hence, accurate and correct diagnosis of the various leukemia subtypes becomes an important first step in the treatment process.
  • [MeSH-major] Decision Making, Computer-Assisted. Fuzzy Logic. Gene Expression. Neural Networks (Computer). Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15617982.001).
  • [ISSN] 0933-3657
  • [Journal-full-title] Artificial intelligence in medicine
  • [ISO-abbreviation] Artif Intell Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


62. Xiong H, Zhang YD, Hu Q, Sun Y, Liu SY, Zhang LQ, Liu AG, Wang GL: [Biological characteristics of T-lineage acute lymphoblastic leukemia in 23 children]. Zhongguo Dang Dai Er Ke Za Zhi; 2010 Aug;12(8):605-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biological characteristics of T-lineage acute lymphoblastic leukemia in 23 children].
  • OBJECTIVE: To investigate the biological characteristics of childhood T-lineage acute lymphoblastic leukemia (T-ALL) and their clinical significance.
  • [MeSH-major] Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20704789.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


63. Chu J, Hong NA, Masuda CA, Jenkins BV, Nelms KA, Goodnow CC, Glynne RJ, Wu H, Masliah E, Joazeiro CA, Kay SA: A mouse forward genetics screen identifies LISTERIN as an E3 ubiquitin ligase involved in neurodegeneration. Proc Natl Acad Sci U S A; 2009 Feb 17;106(7):2097-103
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A mouse forward genetics screen identifies LISTERIN as an E3 ubiquitin ligase involved in neurodegeneration.
  • A mouse neurological mutant, lister, was identified through a genome-wide N-ethyl-N-nitrosourea (ENU) mutagenesis screen.
  • Homozygous lister mice exhibit profound early-onset and progressive neurological and motor dysfunction. lister encodes a RING finger protein, LISTERIN, which functions as an E3 ubiquitin ligase in vitro.
  • Although lister is widely expressed in all tissues, motor and sensory neurons and neuronal processes in the brainstem and spinal cord are primarily affected in the mutant.
  • Pathological signs include gliosis, dystrophic neurites, vacuolated mitochondria, and accumulation of soluble hyperphosphorylated tau.
  • Analysis with a different lister allele generated through targeted gene trap insertion reveals LISTERIN is required for embryonic development and confirms that direct perturbation of a LISTERIN-regulated process causes neurodegeneration.
  • The lister mouse uncovers a pathway involved in neurodegeneration and may serves as a model for understanding the molecular mechanisms underlying human neurodegenerative disorders.
  • [MeSH-major] Mutation. Neurodegenerative Diseases / genetics. Ubiquitin-Protein Ligases / metabolism
  • [MeSH-minor] Alleles. Animals. Axons. Genotype. Homozygote. Humans. Mice. Mice, Inbred C57BL. Models, Biological. Mutagenesis. Phenotype. Tissue Distribution


64. Liljeström B, Aktan-Collan K, Isomaa B, Sarelin L, Uutela A, Groop L, Kääriäinen H, Tuomi T: Genetic testing for maturity onset diabetes of the young: uptake, attitudes and comparison with hereditary non-polyposis colorectal cancer. Diabetologia; 2005 Feb;48(2):242-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority of both diabetic and non-diabetic subjects considered that the MODY3 gene test should be offered either in childhood (50 and 37%) or as a teenager (30 and 37%).


65. Srinivas U, Mahapatra M, Saxena R, Pati HP: Thirty-nine cases of pure red cell aplasia: a single center experience from India. Hematology; 2007 Jun;12(3):245-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thirty-nine cases of pure red cell aplasia: a single center experience from India.
  • Pure red cell aplasia (PRCA) is an uncommon disorder, characterized by transfusion dependent anemia, reticulocytopenia with selective aplasia or paucity of erythroid cells in bone marrow.
  • Immunohistochemistry (IHC) with Glycophorin A showed a mean positive cell % of 8.2 (range 2-16%) and 6.8 (1-9%) in pediatric and adult respectively against a mean of 28% (range 21-39%) in idiopathic thrombocytopenia (ITP) cases.
  • Treatment with prednisone showed good response in a majority of both adults and childhood PRCA.
  • [MeSH-major] Red-Cell Aplasia, Pure / diagnosis

  • Genetic Alliance. consumer health - Pure red cell aplasia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17558701.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glycophorin; 83HN0GTJ6D / Cyclosporine; VB0R961HZT / Prednisone
  •  go-up   go-down


66. Rivero MA, Passucci JA, Rodriguez EM, Parma AE: Role and clinical course of verotoxigenic Escherichia coli infections in childhood acute diarrhoea in Argentina. J Med Microbiol; 2010 Mar;59(Pt 3):345-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role and clinical course of verotoxigenic Escherichia coli infections in childhood acute diarrhoea in Argentina.
  • The aim of this study was to investigate the role and clinical course of verotoxigenic Escherichia coli (VTEC) infections in children with acute diarrhoea from Argentina, the country with the highest worldwide incidence of haemolytic uraemic syndrome (HUS).
  • To accomplish this objective, 437 samples from children up to 6 years old with acute diarrhoea were collected and processed.
  • All of the VTEC isolates produced a cytopathic effect on Vero cell monolayers, confirming the ability to express VT.
  • In conclusion, the data obtained in this study increase our knowledge of the role and clinical course of VTEC infection in childhood acute diarrhoea beyond bloody diarrhoea, and might be considered for the prevention, diagnosis and management of this disease.

  • MedlinePlus Health Information. consumer health - Diarrhea.
  • MedlinePlus Health Information. consumer health - E. Coli Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19850706.001).
  • [ISSN] 1473-5644
  • [Journal-full-title] Journal of medical microbiology
  • [ISO-abbreviation] J. Med. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / DNA, Bacterial; 0 / Escherichia coli Proteins; 0 / Virulence Factors
  •  go-up   go-down


67. Stumpel DJ, Schneider P, van Roon EH, Boer JM, de Lorenzo P, Valsecchi MG, de Menezes RX, Pieters R, Stam RW: Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. Blood; 2009 Dec 24;114(27):5490-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options.
  • MLL-rearranged infant acute lymphoblastic leukemia (ALL) remains the most aggressive type of childhood leukemia, displaying a unique gene expression profile.
  • [MeSH-major] DNA Methylation. Myeloid-Lymphoid Leukemia Protein / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 19 / genetics. Chromosomes, Human, Pair 4 / genetics. Chromosomes, Human, Pair 9 / genetics. Cluster Analysis. CpG Islands / genetics. Cytidine / analogs & derivatives. Cytidine / pharmacology. Dose-Response Relationship, Drug. Gene Expression Profiling. Gene Expression Regulation, Leukemic. Humans. Infant. Jurkat Cells. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19855078.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE18400
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 3690-10-6 / pyrimidin-2-one beta-ribofuranoside; 5CSZ8459RP / Cytidine
  •  go-up   go-down


68. Etzioni A: Defects in the leukocyte adhesion cascade. Clin Rev Allergy Immunol; 2010 Feb;38(1):54-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with this disorder suffer from life-threatening bacterial infections, and in its severe form, death usually occurs in early childhood unless bone marrow transplantation is performed.
  • [MeSH-major] Cell Adhesion / physiology. Leukocyte-Adhesion Deficiency Syndrome / immunology. Leukocyte-Adhesion Deficiency Syndrome / physiopathology. Leukocytes

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Hematol. 2002 Mar;30(3):252-61 [11882363.001]
  • [Cites] Blood. 1999 Dec 15;94(12):3976-85 [10590041.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1629-35 [7632973.001]
  • [Cites] J Clin Invest. 1997 Oct 1;100(7):1725-33 [9312170.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3641-3 [10877554.001]
  • [Cites] J Biol Chem. 2005 Mar 25;280(12):11289-94 [15653671.001]
  • [Cites] Nat Med. 2004 Sep;10(9):982-6 [15334074.001]
  • [Cites] J Clin Invest. 2003 Jan;111(1):51-60 [12511588.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 May;2(5):369-77 [11331911.001]
  • [Cites] Annu Rev Immunol. 2009;27:339-62 [19302044.001]
  • [Cites] Nat Immunol. 2005 May;6(5):497-506 [15834409.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4437-45 [12595312.001]
  • [Cites] J Biol Chem. 2007 Apr 6;282(14):10762-72 [17276979.001]
  • [Cites] J Allergy Clin Immunol. 1998 Aug;102(2):323-4 [9723680.001]
  • [Cites] Cells Tissues Organs. 2002;172(3):161-73 [12476046.001]
  • [Cites] N Engl J Med. 1992 Dec 17;327(25):1789-92 [1279426.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1182-4 [17244687.001]
  • [Cites] Blood. 2009 May 7;113(19):4740-6 [19064721.001]
  • [Cites] J Biol Chem. 1999 Sep 10;274(37):25986-9 [10473542.001]
  • [Cites] J Clin Invest. 1999 Jan;103(1):97-106 [9884339.001]
  • [Cites] FEBS J. 2006 Oct;273(19):4390-8 [16956371.001]
  • [Cites] Curr Opin Mol Ther. 2000 Aug;2(4):383-8 [11249768.001]
  • [Cites] Blood. 2008 Jan 1;111(1):209-18 [17875809.001]
  • [Cites] J Clin Invest. 1998 Jun 1;101(11):2438-45 [9616215.001]
  • [Cites] Nat Med. 2008 Jan;14(1):93-7 [18157138.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2591 [18779414.001]
  • [Cites] Nat Med. 2009 Mar;15(3):313-8 [19234460.001]
  • [Cites] Pediatr Res. 1996 Feb;39(2):191-8 [8825786.001]
  • [Cites] Trends Immunol. 2003 Oct;24(10):561-6 [14552841.001]
  • [Cites] J Biol Chem. 2003 Jul 18;278(29):26727-33 [12738772.001]
  • [Cites] Nat Immunol. 2005 Dec;6(12):1182-90 [16369557.001]
  • [Cites] Blood. 2006 May 15;107(10):3959-66 [16455955.001]
  • [Cites] Immunodefic Rev. 1988;1(1):39-54 [3078709.001]
  • [Cites] J Clin Invest. 2007 Jun;117(6):1699-707 [17492052.001]
  • [Cites] Nat Med. 2009 Mar;15(3):300-5 [19234461.001]
  • [Cites] Blood. 2001 Feb 1;97(3):767-76 [11157496.001]
  • [Cites] Nat Genet. 2001 May;28(1):73-6 [11326280.001]
  • [Cites] J Clin Invest. 1993 Jun;91(6):2893-7 [7685776.001]
  • [Cites] EMBO Rep. 2008 Dec;9(12):1203-8 [18997731.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1033-6 [14551137.001]
  • [Cites] Fertil Steril. 2006 Feb;85(2):494.e15-8 [16595236.001]
  • [Cites] J Exp Med. 2007 Jul 9;204(7):1571-82 [17576779.001]
  • [Cites] Blood. 1994 Oct 1;84(7):2068-101 [7522621.001]
  • [Cites] Nat Med. 2009 Mar;15(3):306-12 [19234463.001]
  • (PMID = 19437145.001).
  • [ISSN] 1559-0267
  • [Journal-full-title] Clinical reviews in allergy & immunology
  • [ISO-abbreviation] Clin Rev Allergy Immunol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Integrins; 0 / Selectins
  • [Number-of-references] 45
  •  go-up   go-down


69. Maragno L, Casseb J, Fukumori LM, Sotto MN, Duarte AJ, Festa-Neto C, Sanches JA: Human T-cell lymphotropic virus type 1 infective dermatitis emerging in adulthood. Int J Dermatol; 2009 Jul;48(7):723-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human T-cell lymphotropic virus type 1 infective dermatitis emerging in adulthood.
  • BACKGROUND: Infective dermatitis (ID) is a rare dermatologic condition of childhood that has been linked to human T-cell lymphotropic virus type 1 (HTLV-1).
  • Histopathologic study showed lymphocytic epidermotropism in two cases.
  • CONCLUSIONS: Although many authors have considered ID to be a form of childhood dermatitis, we have described four cases that fulfilled the major criteria for ID, except for onset in adulthood.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19570078.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Hepworth SJ, Feltbower RG, McKinney PA: Childhood leukaemias and CNS tumours: correlation of international incidence rates. Eur J Cancer; 2006 Mar;42(4):509-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood leukaemias and CNS tumours: correlation of international incidence rates.
  • Childhood leukaemia has a potential infectious aetiology whilst infections may also be linked to paediatric central nervous system (CNS) tumours.
  • Using data from 29 countries we investigated the correlation between international incidence rates of childhood leukaemia and CNS tumours, focusing on acute lymphoblastic leukaemia (ALL), astrocytoma and ependymoma-subtypes that are hypothesised to have an infectious aetiology.
  • National incidence rates of childhood ALL and astrocytomas were highly correlated and this may reflect a common environmental cause whose origin may be infectious in nature.
  • Variation in levels of ascertainment may partially explain this, although childhood environmental exposures related to infections will also be affected by levels of affluence.
  • [MeSH-major] Astrocytoma / epidemiology. Central Nervous System Neoplasms / epidemiology. Ependymoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410049.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


71. Kadan-Lottick NS, Dinu I, Wasilewski-Masker K, Kaste S, Meacham LR, Mahajan A, Stovall M, Yasui Y, Robison LL, Sklar CA: Osteonecrosis in adult survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol; 2008 Jun 20;26(18):3038-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteonecrosis in adult survivors of childhood cancer: a report from the childhood cancer survivor study.
  • PURPOSE: Osteonecrosis (ON) is a potentially serious complication of therapy in survivors of childhood cancer.
  • PATIENTS AND METHODS: The rate of self-reported ON was determined for 9,261 patients enrolled onto the Childhood Cancer Survivor Study, a cohort of 5-year survivors of childhood cancer diagnosed from 1970 to 1986, and compared with the rate in a random sample of 2,872 siblings of survivors.
  • The RR was greatest among survivors of stem-cell transplantation for acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), and chronic myelogenous leukemia (RR = 26.9, 66.5, and 93.1, respectively).
  • CONCLUSION: ON among long-term survivors of childhood cancer is rare.
  • However, compared with siblings, childhood cancer survivors have a significantly increased relative rate of ON, particularly those who were older at diagnosis and who received dexamethasone or radiation therapy.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Osteonecrosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18565890.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA055727; United States / NCRR NIH HHS / RR / KL2 RR024138; United States / NCI NIH HHS / CA / U24-CA-55727
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


72. Ward KN, Bryant NJ, Andrews NJ, Bowley JS, Ohrling A, Verity CM, Ross EM, Miller E: Risk of serious neurologic disease after immunization of young children in Britain and Ireland. Pediatrics; 2007 Aug;120(2):314-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: We sought to investigate the risk of serious neurologic disease after immunization in early childhood.
  • The self-controlled case-series method was used to investigate associations between immunization and acute potential adverse events.
  • The risk periods investigated were 0 to 3 and 0 to 7 days post-diphtheria, tetanus, whole cell pertussis, Haemophilus influenzae type b or meningococcal C conjugate vaccine and 6 to 11 and 15 to 35 days post-measles, mumps, rubella vaccine.

  • MedlinePlus Health Information. consumer health - Immunization.
  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671057.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / 051350/Z
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Measles Vaccine; 0 / Meningococcal Vaccines; 0 / Mumps Vaccine; 0 / Rubella Vaccine; 0 / serogroup C meningococcal conjugate vaccine
  •  go-up   go-down


73. Karas-Kuzelicki N, Jazbec J, Milek M, Mlinaric-Rascan I: Heterozygosity at the TPMT gene locus, augmented by mutated MTHFR gene, predisposes to 6-MP related toxicities in childhood ALL patients. Leukemia; 2009 May;23(5):971-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterozygosity at the TPMT gene locus, augmented by mutated MTHFR gene, predisposes to 6-MP related toxicities in childhood ALL patients.
  • [MeSH-major] 6-Mercaptopurine / pharmacology. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Methyltransferases / genetics. Mutation / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Drug-Related Side Effects and Adverse Reactions. Female. Hematopoietic Stem Cell Transplantation. Heterozygote. Humans. Male. Retrospective Studies

  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18987660.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] E7WED276I5 / 6-Mercaptopurine; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 2.1.1.- / Methyltransferases; EC 2.1.1.67 / thiopurine methyltransferase
  •  go-up   go-down


74. Palo AK, Sahu P, Choudhury RC: Etoposide-induced cytogenotoxicity in mouse spermatogonia and its potential transmission. J Appl Toxicol; 2005 Mar-Apr;25(2):94-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Such transmission of effects from the post-chemotherapeutic childhood cancer survivors is of serious concern but very little attention has been given so far to such studies.
  • In the present study, the clastogenic potential of three different doses of etoposide (10, 15 and 20 mg kg(-1)) in the male germline of mice was assessed from the dividing spermatogonia after a single exposure for one cell cycle duration at 24 h post-treatment.

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 John Wiley & Sons, Ltd.
  • (PMID = 15744785.001).
  • [ISSN] 0260-437X
  • [Journal-full-title] Journal of applied toxicology : JAT
  • [ISO-abbreviation] J Appl Toxicol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


75. Caughey RW, Michels KB: Birth weight and childhood leukemia: a meta-analysis and review of the current evidence. Int J Cancer; 2009 Jun 1;124(11):2658-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Birth weight and childhood leukemia: a meta-analysis and review of the current evidence.
  • A growing body of evidence suggests that childhood leukemia may be initiated in utero when lymphoid and myeloid cells are not fully differentiated and are particularly susceptible to malignant transformation.
  • A fixed effects meta-analysis examining the association between birth weight and childhood leukemia was conducted including 32 studies and 16,501 cases of all types of leukemia (OL), 10,974 cases of acute lymphoblastic leukemia (ALL), and 1,832 cases of acute myeloid leukemia (AML).
  • Low birth weight was not associated with overall and ALL leukemia, but with AML (OR = 1.50; 95% CI: 1.05, 2.13).
  • The combined available evidence from observational studies suggests that high birth weight is associated with an increased risk of overall leukemia and ALL.
  • [MeSH-major] Birth Weight. Leukemia, Myeloid, Acute / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Birth Weight.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173295.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Number-of-references] 62
  •  go-up   go-down


76. Gill HK, Keoh TS, Dhaliwal JS, Moore S, Kim TS, Hassan R, Karim FA, Zakaria Z, Murad S, Mohamed M, Li Ho CM, Ibrahim H, Rahman EJ: TEL-AML1 frequency in multi-ethnic Malaysian pediatric acute lymphoblastic leukemia. Cancer Genet Cytogenet; 2005 Jan 15;156(2):129-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TEL-AML1 frequency in multi-ethnic Malaysian pediatric acute lymphoblastic leukemia.
  • Eighty-eight multi-ethnic Malaysian pediatric acute lymphoblastic leukemia (ALL) patients were screened for the TEL-AML1 rearrangement by reverse transcription-polymerase chain reaction (RT-PCR).
  • All patients, including 1 with an unusual blast cell morphology who suffered an early relapse and death, were characteristic TEL-AML1 cases in cell count, age, ALL subset classification, and fusion transcript expressed.
  • This study shows that in Malaysia, TEL-AML1 is found in the same distinct ALL subset and at a similar frequency as in other diverse childhood ALL cohorts.
  • [MeSH-major] Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15642392.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


77. Nwosu BU, Gourgiotis L, Gershengorn MC, Neumann S: A novel activating mutation in transmembrane helix 6 of the thyrotropin receptor as cause of hereditary nonautoimmune hyperthyroidism. Thyroid; 2006 May;16(5):505-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They all developed goiter in childhood and showed a suppressed TSH and elevated thyroxine (T(4)).
  • [MeSH-minor] Adolescent. Base Sequence. Cell Line. Cyclic AMP / metabolism. DNA Mutational Analysis. Family Health. Female. Germ-Line Mutation. Humans. Male. Molecular Sequence Data. Protein Structure, Tertiary

  • Genetic Alliance. consumer health - Hyperthyroidism, nonautoimmune.
  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16756474.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Thyrotropin; E0399OZS9N / Cyclic AMP
  •  go-up   go-down


78. Phillips MF, Quinlivan R: Calcium antagonists for Duchenne muscular dystrophy. Cochrane Database Syst Rev; 2008;(4):CD004571
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Duchenne muscular dystrophy (DMD) is a progressive muscle condition starting in childhood, leading to severe disability and a shortened life span.
  • Calcium accumulates in dystrophic muscle cells and plays a role in cell damage.

  • Genetic Alliance. consumer health - Duchenne Muscular Dystrophy.
  • Genetic Alliance. consumer health - Muscular dystrophy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VERAPAMIL HYDROCHLORIDE .
  • Hazardous Substances Data Bank. Nifedipine .
  • Hazardous Substances Data Bank. DILTIAZEM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18843663.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calcium Channel Blockers; CJ0O37KU29 / Verapamil; EE92BBP03H / Diltiazem; I9ZF7L6G2L / Nifedipine; R7PLA2DM0J / Flunarizine
  • [Number-of-references] 65
  •  go-up   go-down


79. Kadan-Lottick NS, Brouwers P, Breiger D, Kaleita T, Dziura J, Northrup V, Chen L, Nicoletti M, Bostrom B, Stork L, Neglia JP: Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia. J Clin Oncol; 2009 Dec 10;27(35):5986-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia.
  • PURPOSE: For the majority of children with acute lymphoblastic leukemia (ALL), CNS prophylaxis consists of either intrathecal (IT) methotrexate or triple IT therapy (ie, methotrexate with both cytarabine and hydrocortisone).
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cognition / drug effects. Methotrexate / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


80. Aricò M, Valsecchi MG, Rizzari C, Barisone E, Biondi A, Casale F, Locatelli F, Lo Nigro L, Luciani M, Messina C, Micalizzi C, Parasole R, Pession A, Santoro N, Testi AM, Silvestri D, Basso G, Masera G, Conter V: Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy. J Clin Oncol; 2008 Jan 10;26(2):283-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
  • PURPOSE: Between May 1995 and August 2000 the Associazione Italiana di Ematologia Oncologia Pediatrica conducted the ALL-95 study for risk-directed, Berlin-Frankfurt-Muenster (BFM) -oriented therapy of childhood acute lymphoblastic leukemia, aimed at exploring treatment reduction in standard-risk patients (SR) and intensification during continuation therapy in intermediate-risk patients (IR) as randomized questions and treatment intensification in high-risk patients (HR).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18182669.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; AIEOP acute lymphoblastic leukemia protocol
  •  go-up   go-down


81. Chidzonga MM, Mahomva L, Makunike-Mutasa R, Masanganise R: Xeroderma pigmentosum: a retrospective case series in Zimbabwe. J Oral Maxillofac Surg; 2009 Jan;67(1):22-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Squamous cell carcinoma (SCC) was present on the skin, lip, and tongue in most patients.
  • It is common in early childhood with severe photosensitivity, photophobia, and eventual blindness.
  • [MeSH-major] African Continental Ancestry Group. Carcinoma, Squamous Cell / pathology. Mouth Neoplasms / pathology. Skin Neoplasms / pathology. Xeroderma Pigmentosum / ethnology


82. Mullighan CG: Genomic analysis of acute leukemia. Int J Lab Hematol; 2009 Aug;31(4):384-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic analysis of acute leukemia.
  • Acute leukemia is the commonest childhood cancer and a major cause of morbidity from hematologic malignancies in adults.
  • Acute lymphoblastic leukemia (ALL) is commonest in children, and acute myeloid leukemia (AML) is more frequent in adults.
  • Apart from childhood ALL, the prognosis of acute leukemia is suboptimal, with many patients experiencing relapse, which carries a poor prognosis, or toxicities from nonspecific therapies.
  • Recent years have witnessed great interest in the application of high-resolution, genome wide approaches to the study of acute leukemia.
  • These studies have identified multiple novel genetic alterations targeting critical cellular pathways that contribute to leukemogenesis, including alterations of genes regulating lymphoid development, tumor suppressors, apoptosis regulators, and oncogenes.
  • These studies have demonstrated the power of genome-wide approaches to identify new lesions in acute leukemia, and suggest that ongoing genomic analyses, including deep resequencing and epigenetic analysis, will continue to yield novel, clinically relevant insights into the pathogenesis of this disease.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19486196.001).
  • [ISSN] 1751-553X
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 112
  •  go-up   go-down


83. Wraith JE, Imrie J: New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat. Ther Clin Risk Manag; 2009;5:877-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Miglustat (Zavesca(R)), a reversible inhibitor of glycosphingolipid synthesis, has recently been authorized in the European Union, Brazil and South Korea for the treatment of progressive neurological symptoms in adult and pediatric patients, and represents the first specific treatment for NP-C.
  • Findings demonstrated clinically relevant beneficial effects of miglustat on neurological disease progression in adult, juvenile and pediatric patients with NP-C, particularly those diagnosed in late childhood (6-11 years) and in juveniles and adults (12 years and older), compared with those diagnosed in early childhood (younger than 6 years).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. DrugBank: Data: Chemical .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Biol. 2001 Aug 21;11(16):1283-7 [11525744.001]
  • [Cites] Mol Genet Metab. 2009 Nov;98(3):243-9 [19656703.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):23594-9 [12709427.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):5886-91 [15071184.001]
  • [Cites] Neurobiol Dis. 2004 Aug;16(3):654-8 [15262277.001]
  • [Cites] Clin Ther. 2005 Aug;27(8):1215-27 [16199246.001]
  • [Cites] J Neurol Sci. 2006 Nov 1;249(1):1-6 [16814322.001]
  • [Cites] Reprod Biol Endocrinol. 2007;5:1 [17241468.001]
  • [Cites] J Inherit Metab Dis. 2007 Oct;30(5):826 [17603755.001]
  • [Cites] Xenobiotica. 2007 Mar;37(3):298-314 [17624027.001]
  • [Cites] Mov Disord. 2008 Jan;23(1):124-8 [17973331.001]
  • [Cites] Nat Med. 2008 Nov;14(11):1247-55 [18953351.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2377-82 [19171898.001]
  • [Cites] Neurology. 2009 Mar 24;72(12):1083-6 [19307542.001]
  • [Cites] Mol Genet Metab. 2009 Nov;98(3):250-4 [19616462.001]
  • [Cites] J Psychiatr Res. 1975 Nov;12(3):189-98 [1202204.001]
  • [Cites] J Biol Chem. 1988 Mar 5;263(7):3411-7 [3277970.001]
  • [Cites] Clin Genet. 1988 May;33(5):331-48 [3378364.001]
  • [Cites] Biochim Biophys Acta. 1980 Sep 8;619(3):669-79 [6257302.001]
  • [Cites] Ann Neurol. 1983 Oct;14(4):492-3 [6314876.001]
  • [Cites] Biochim Biophys Acta. 1983 Jan 7;750(1):178-84 [6824712.001]
  • [Cites] Ann Neurol. 1982 Sep;12(3):284-8 [7137965.001]
  • [Cites] J Biol Chem. 1994 Mar 18;269(11):8362-5 [8132559.001]
  • [Cites] Biochim Biophys Acta. 1994 May 25;1226(2):138-44 [8204660.001]
  • [Cites] JAMA. 1996 Aug 21;276(7):561-4 [8709406.001]
  • [Cites] Science. 1997 Jul 11;277(5323):228-31 [9211849.001]
  • [Cites] JAMA. 1999 Jan 20;281(3):249-54 [9918480.001]
  • [Cites] Neurochem Res. 1999 Apr;24(4):481-9 [10227680.001]
  • [Cites] Bone Marrow Transplant. 1999 Jul;24(1):103-7 [10435744.001]
  • [Cites] Lancet. 2000 Apr 29;355(9214):1481-5 [10801168.001]
  • [Cites] Neurology. 2000 Dec 12;55(11):1621-6 [11113214.001]
  • [Cites] Science. 2000 Dec 22;290(5500):2298-301 [11125141.001]
  • [Cites] Am J Hum Genet. 2001 Nov;69(5):1013-21 [11567215.001]
  • [Cites] J Clin Invest. 2002 Jun;109(12):1541-50 [12070301.001]
  • [Cites] J Lipid Res. 2003 Feb;44(2):243-53 [12576506.001]
  • [Cites] Clin Genet. 2003 Oct;64(4):269-81 [12974729.001]
  • [Cites] J Biol Chem. 2004 Jun 18;279(25):26167-75 [15078881.001]
  • [Cites] Biochim Biophys Acta. 2004 Oct 11;1685(1-3):28-37 [15465424.001]
  • [Cites] Mol Genet Metab. 2005 Sep-Oct;86(1-2):220-32 [16126423.001]
  • [Cites] Tohoku J Exp Med. 2006 Jul;209(3):263-7 [16778374.001]
  • [Cites] Hum Reprod. 2007 Mar;22(3):702-7 [17067996.001]
  • [Cites] J Inherit Metab Dis. 2007 Feb;30(1):51-9 [17160617.001]
  • [Cites] Am J Med Genet A. 2007 Jun 1;143A(11):1204-11 [17497724.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2296-301 [17609429.001]
  • [Cites] Brain Res Rev. 2008 Mar;57(2):410-20 [17629950.001]
  • [Cites] Lancet Neurol. 2007 Sep;6(9):765-72 [17689147.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15223-4 [18832164.001]
  • [Cites] Mol Genet Metab. 2009 Feb;96(2):55-8 [19013089.001]
  • [Cites] Am J Pathol. 2009 Jan;174(1):14-20 [19056848.001]
  • [Cites] Biochim Biophys Acta. 2009 Jul;1791(7):671-8 [19232397.001]
  • [Cites] Cell. 2009 Jun 26;137(7):1213-24 [19563754.001]
  • [Cites] Mol Genet Metab. 2009 Sep-Oct;98(1-2):152-65 [19647672.001]
  • [Cites] Blood Cells Mol Dis. 2002 Mar-Apr;28(2):127-33 [12064906.001]
  • (PMID = 19956552.001).
  • [ISSN] 1176-6336
  • [Journal-full-title] Therapeutics and clinical risk management
  • [ISO-abbreviation] Ther Clin Risk Manag
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2781062
  • [Keywords] NOTNLM ; NP-C / Niemann-Pick disease type C / Zavesca® / miglustat
  •  go-up   go-down


84. Wiemels J: Chromosomal translocations in childhood leukemia: natural history, mechanisms, and epidemiology. J Natl Cancer Inst Monogr; 2008;(39):87-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal translocations in childhood leukemia: natural history, mechanisms, and epidemiology.
  • The root causes of childhood leukemia will be discovered by understanding the mechanism of mutations in the context of the cell of origin and time in life of the child.
  • Molecular studies using archival DNA samples and twins with concordant leukemia have demonstrated that most childhood leukemia translocation subtypes occur before to birth and occur in early progenitors.
  • Leukemia like all cancers is the product of two or more genetic and/or epigenetic events, and the natural history and mechanisms of these two events are likely independent, resulting in two or more "causes" of leukemia.
  • [MeSH-major] Leukemia / epidemiology. Leukemia / genetics. Oncogene Proteins, Fusion / genetics. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18648011.001).
  • [ISSN] 1052-6773
  • [Journal-full-title] Journal of the National Cancer Institute. Monographs
  • [ISO-abbreviation] J. Natl. Cancer Inst. Monographs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; EC 2.7.7.- / VDJ Recombinases
  •  go-up   go-down


85. Zheng C, Liu X, Wu J, Cai X, Zhu W, Sun Z: Which steroids should we choose for the treatment of adult acute lymphoblastic leukemia? Am J Hematol; 2010 Oct;85(10):817-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Which steroids should we choose for the treatment of adult acute lymphoblastic leukemia?
  • Corticosteroids are essential and one of the mainstays in the treatment of acute lymphoblastic leukemia (ALL).
  • In vitro assays show that dexamethasone(DXM) is five to six times more cytotoxic to leukemic lymphoblasts than prednisolone (PDN) [1], and the use of DXM as an alternative drug for PDN is an important issue in the treatment of childhood ALL.
  • The current randomized comparisons in childhood ALL indicated a statistically significant and clinically important decrease in rate of isolated central nervous system (CNS) relapses and an increase in event-free survival (EFS) with DXM.
  • Recently, Labar et al. [2] reported their first investigation in comparison of the antileukemic activity and toxicity between DXM and PDN for adult patients with ALL and lymphoblastic lymphoma (LBL) through a randomized clinical trial (the ALL-4 trial of the EORTC Leukemia Group), and the author concluded that DXM as a steroid therapy for adult patients with ALL/LBL did not show any benefit compared with PDN, which did not support the experience from several other pediatric studies.
  • Most of the patients in pediatric trials were standard risk (SR) ALL.
  • [MeSH-major] Dexamethasone. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Prednisolone

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20815080.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Letter; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 9PHQ9Y1OLM / Prednisolone; EC 3.5.1.1 / Asparaginase; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


86. Moftakhar P, Fan X, Hurvitz CH, Black KL, Danielpour M: Long-term survival in a child with a central nervous system medulloepithelioma. J Neurosurg Pediatr; 2008 Nov;2(5):339-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Central nervous system medulloepitheliomas are extremely rare and malignant (World Health Organization Grade IV) primitive neuroectodermal tumors (PNETs) that arise in childhood.
  • A review of all the published cases of medulloepithelioma is also presented, and alternative treatment strategies for PNET tumors, including high-dose chemotherapy with stem-cell rescue, are discussed.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Combined Modality Therapy. Disease-Free Survival. Female. Hematopoietic Stem Cell Transplantation. Humans. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976104.001).
  • [ISSN] 1933-0707
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 46
  •  go-up   go-down


87. Renois F, Jacques J, Talmud D, Deslée G, Lévêque N, Andréoletti L: Respiratory echovirus 30 and coxsackievirus B5 can induce production of RANTES, MCP-1 and IL-8 by human bronchial epithelial cells. Virus Res; 2010 Sep;152(1-2):41-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human Enteroviruses (HEV) (picornaviridae) are considered as one the major viral causes of childhood acute respiratory wheezing illnesses including bronchiolitis and asthma exacerbation.
  • [MeSH-minor] Cell Line. Cells, Cultured. Epithelial Cells / immunology. Epithelial Cells / virology. Humans

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20540976.001).
  • [ISSN] 1872-7492
  • [Journal-full-title] Virus research
  • [ISO-abbreviation] Virus Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CCL2 protein, human; 0 / Chemokine CCL2; 0 / Chemokine CCL5; 0 / Interleukin-8
  •  go-up   go-down


88. Heni M, Haupt A, Schäfer SA, Ketterer C, Thamer C, Machicao F, Stefan N, Staiger H, Häring HU, Fritsche A: Association of obesity risk SNPs in PCSK1 with insulin sensitivity and proinsulin conversion. BMC Med Genet; 2010;11:86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rare mutations in gene PCSK1, encoding this enzyme, cause childhood obesity and abnormal glucose homeostasis with elevated proinsulin concentrations.
  • We studied whether these SNPs influence the prediabetic traits insulin resistance, beta-cell dysfunction, or glucose intolerance.

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Res. 1999 Nov 27;848(1-2):45-62 [10701998.001]
  • [Cites] Arch Intern Med. 2008 Aug 11;168(15):1609-16 [18695074.001]
  • [Cites] J Appl Physiol (1985). 2001 May;90(5):1777-87 [11299268.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):1921-35 [12057895.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10299-304 [12136131.001]
  • [Cites] FASEB J. 2003 Jul;17(10):1215-27 [12832286.001]
  • [Cites] J Clin Invest. 2003 Nov;112(10):1550-60 [14617756.001]
  • [Cites] Diabetes. 2004 Jul;53(7):1857-65 [15220211.001]
  • [Cites] Clin Lab. 2004;50(9-10):567-73 [15481632.001]
  • [Cites] N Engl J Med. 1995 Nov 23;333(21):1386-90 [7477119.001]
  • [Cites] Front Neuroendocrinol. 1995 Oct;16(4):322-61 [8557169.001]
  • [Cites] Nat Genet. 1997 Jul;16(3):303-6 [9207799.001]
  • [Cites] Int J Obes Relat Metab Disord. 1997 Jul;21(7):567-73 [9226487.001]
  • [Cites] Diabetes. 1997 Dec;46(12):1990-5 [9392485.001]
  • [Cites] Curr Opin Chem Biol. 1998 Feb;2(1):31-9 [9667917.001]
  • [Cites] Nat Genet. 1998 Nov;20(3):304-8 [9806554.001]
  • [Cites] Diabetes Care. 1999 Sep;22(9):1462-70 [10480510.001]
  • [Cites] Diabetologia. 2005 Nov;48(11):2282-91 [16205883.001]
  • [Cites] Science. 2007 May 11;316(5826):889-94 [17434869.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Sep;92(9):3369-73 [17595246.001]
  • [Cites] Diabetologia. 2008 Apr;51(4):597-601 [18264689.001]
  • [Cites] Int J Biochem Cell Biol. 2008;40(6-7):1111-25 [18343183.001]
  • [Cites] Clin Biochem. 2008 Jul;41(10-11):812-7 [18402781.001]
  • [Cites] Nat Genet. 2008 Aug;40(8):943-5 [18604207.001]
  • [Cites] Diabetes Care. 2000 Mar;23(3):295-301 [10868854.001]
  • (PMID = 20534142.001).
  • [ISSN] 1471-2350
  • [Journal-full-title] BMC medical genetics
  • [ISO-abbreviation] BMC Med. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / C-Peptide; 0 / Insulin; 9035-68-1 / Proinsulin; IY9XDZ35W2 / Glucose
  • [Other-IDs] NLM/ PMC2898666
  •  go-up   go-down


89. Deng HY, Gao Y, Li YJ, Zhong F: [Antineutrophil cytoplasmic autoantibody-associated rapidly progressive glomerulonephritis in children]. Zhongguo Dang Dai Er Ke Za Zhi; 2008 Feb;10(1):25-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinical characteristics of childhood antineutrophil cytoplasmic autoantibody (ANCA)-associated rapidly progressive glomerulonephritis.
  • A great quantity of inflammatory cell infiltration and swollen endotheliocytes of small vessels as well as vessel wall edema or necrosis were found in the interstitium.

  • Genetic Alliance. consumer health - Glomerulonephritis.
  • Hazardous Substances Data Bank. PREDNISONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18289465.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Antineutrophil Cytoplasmic; VB0R961HZT / Prednisone
  •  go-up   go-down


90. García-Casado Z, Cervera J, Verdeguer A, Tasso M, Valencia A, Pajuelo JC, Mena-Duran AV, Barragán E, Blanes M, Bolufer P, Sanz MA: High-level amplification of the RUNX1 gene in two cases of childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet; 2006 Oct 15;170(2):171-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-level amplification of the RUNX1 gene in two cases of childhood acute lymphoblastic leukemia.
  • The RUNX1 (alias AML1) gene is involved in several patterns of chromosomal translocations and rearrangements associated with human acute leukemia.
  • Often, multiple signals for AML1 have been observed in childhood acute lymphoblastic leukemia (ALL) due to frequent polysomy of chromosome 21 in this leukemia.
  • Additionally, high-level amplification of AML1, in the absence of polysomy of chromosome 21, has been reported in childhood ALL.
  • We report two new cases of childhood ALL, without a ETV6/RUNX1 (alias TEL/AML1) rearrangement, showing high-level amplification of the AML1 gene detected by fluorescence in situ hybridization and comparative genomic hybridization analysis.
  • The similarity in the clinicobiologic features of all the cases with this abnormality points to an emerging molecular cytogenetic subgroup of B-cell precursor ALL and suggests a possible dosage effect of AML1 in the pathogenesis of leukemia.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Gene Amplification. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17011991.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / RUNX1 protein, human
  •  go-up   go-down


91. Kroczka S, Steczkowska-Klucznik M, Romaniszyn A: [Auditory evoked potentials in patients after acute children's lymphoblastic leukemia treatment]. Przegl Lek; 2006;63(11):1205-9
PDF icon [Fulltext service] Get downloadable